UNIVERSITA' DEGLI STUDI DI ROMA
ToVergata

PhD Course of Immunology

2000-2004

Coordinated by Professor Gino Doria

Title

Bacillus Calmette-Guerin (BCG) and environmental mycobacteria divert Dendritic Cell functions interfering with the differentiation of precursors into competent APCs

Implications for tuberculosis protection

Dr. Angelo Martino

Tutor: Professor Vittorio Colizzi

National Institute for Infectious Diseases Lazzaro Spallanzani- IRCCS

2004

*"Lo scienziato non è l'uomo che fornisce le vere risposte:
è quello che pone le vere domande"*

Claude Lévi Strauss

Alla memoria
di mia madre Giovanna
e a mio padre Giuseppe

Grazie

Index

Abstract

Human monocytes can differentiate into dendritic cells (DCs) according to the nature of environmental signals. We tested here whether the infection with the live tuberculosis vaccine Bacillus Calmette-Guerin (**BCG**), that is known to be limited in preventing pulmonary tuberculosis, modulate monocytes and DCs differentiation. We found that monocytes infected with BCG differentiate into CD1a$^-$ DCs (**BCG-DCs**) in the presence of GM-CSF and IL-4 and acquired a mature phenotype in the absence of maturation stimuli. In addition, BCG-DCs produced pro-inflammatory cytokines (**TNF-α, IL-1β, and IL-6**) and IL-10 but not IL-12. BCG-DCs were able to stimulate allogeneic T lymphocytes to a similar degree as DCs generated in the absence of infection. However, BCG-DCs induced IL-4 production when co-cultured with human cord-blood mononuclear cells.

Since environmental mycobacteria can interfere with BCG efficacy in preventing tuberculosis in some tropical areas, we verify whether this capacity to interfere with DCs functions was a feature common to environmental mycobacteria. To this aim, we infected DCs precursors with *Mycobacterium smegmatis* (***Msm***) to generate DCs. We found that *Msm*-infected monocytes differentiate into DCs with the same phenotype of BCG-DCs but some differences in the capacity to produce immunoregulatory cytokines and polarize naïve CD4$^+$ T cells.

The induction of IL-4 production by DCs generated from BCG-infected monocytes could explain one of the mechanisms for the failure of the BCG vaccine to prevent pulmonary tuberculosis.

1. Introduction

Immunology of Mycobacterium tuberculosis infection

Tuberculosis is a global emergency. One third of the world's population is infected, and although only about 5-10 % develops active disease during the first few years following exposure [1], this still results in a massive case load, with eight million new cases each year, and three million deaths. Moreover, the percentage that progresses to disease is increasing. Tuberculosis is one of the first secondary infections to be activated in human immunodeficiency virus (**HIV**)-positive individuals [2]. Moreover, the stresses of poverty, malnutrition and war, increase the rate of reactivation for reasons discussed later. Even in the developed countries, the disease distribution parallels the distribution of poverty [3]. Meanwhile, the breakdown of healthcare systems is leading to incomplete case and contact tracing, incomplete treatment, and the increase in drug resistance. In some parts of the world, many of the available drugs are fake or out of date [4]. In many areas, existing treatment is probably doing more harm than good, as incomplete treatment regimen select for drug resistance. Multidrug resistant tuberculosis is spreading at an alarming rate, and invading Western Europe from Eastern block countries such as Estonia. There were more cases of tuberculosis in 1999 than ever before in the history of humanity.

An important reason for the current failure to control tuberculosis is the fact that even the best available treatment must be continued for at least 6 months. This treatment regimen is not a realistic proposition in most developing countries, or even in the inner cities of rich ones, because the patients feel well after a few weeks and stop taking the drugs. The world health organization (**WHO**) now admits that directly observed therapy

short-course (DOTS), in which the patient is supervised while taking every dose of therapy helps but does not solve the problem [5].

There are two correlated reasons for the requirement for 6-month regimen. The first is obvious and often discussed. The chemotherapy kills the vast majority of the bacteria within a few days, but there are subpopulations of persisters [6]. It is not clear whether these organisms are in true stationary phase [7] or merely replicating extremely slow. Nor is it clear where they are located. Most authors assume that they are in old lesions or sites of fibrosis or calcification, where oxygen availability may be low. However, in a forgotten paper published in 1927, Opie and Aronson reported that 80% of tuberculosis lesions were already sterile 5 years after the primary infection, whereas live bacilli could be found in macroscopically normal lung tissue [8]. The fact that metronidazole, a drug that should be active in a model of latent infection in mice, implies that live organisms also persist in well-oxygenated sites in this species [9]. Not only do persister organisms cause problems for the treatment, but they also constitute an important source of infection. They can persist for the rest of the life of the individual, and, at least in countries with low or moderate tuberculosis endemicity, many cases of tuberculosis result from reactivation of latent infection [10].

The other reason for the need for prolonged treatment is usually overlooked. Most tuberculosis patients have a necrotizing pattern of response to *Mycobacterium tuberculosis,* analogous to the phenomenon first noted by Koch [11] in guinea pigs. There is overwhelming evidence that the Koch phenomenon does not correlate with optimal protective immunity to tuberculosis. Indeed pre-immunization of animals so that they have a Koch phenomenon before they are challenged with virulent *Mycobacterium tuberculosis* results in a clear and reproducible increase in susceptibility to the disease, compared to non-immunized controls [12]. Its relevant point is that this inappropriate

pattern of response may not correct itself rapidly during treatment. Therefore if chemotherapy is stopped at 3 months, relapse rates are high even when chemotherapy was an optimal rifampicin-containing one that achieved sputum negativity well before 3 months, and in spite of the fact that there are very few live organism in the patients' tissues at this time [13]. We therefore need to understand the differences between protective immunity and the Koch phenomenon, and the factors that determine which response pattern is present. The ultimate objective is to learn to replace the pathological response with the protective one very large treatment.

Mycobacterium tuberculosis (**MTB**) is an intracellular pathogen with the capacity to persist in the early phagosomal compartment [14] in professional phagocytes. It arrests phagosome maturation at an early stage and strongly inhibits phagolysosome fusion [15]. Based on Lurie's studies in rabbits [16], four stages of pulmonary tuberculosis have been distinguished [17]. Initially, there is the inhalation of tubercle bacilli (**first stage**). Alveolar macrophages ingest bacilli and often destroy them. At this stage, the destruction of mycobacteria depends on the intrinsic microbicidal capacity of host phagocytes and virulence factors of the ingested bacteria. Mycobacteria, which escape the initial intracellular destruction, will multiply, and this will lead to disruption of the macrophages. When this happens, blood monocytes and other inflammatory cells are attracted to the lung (**second stage**). These monocytes will differentiate into macrophages or dendritic cells, which again readily ingest but do not destroy the mycobacteria. In this symbiotic stage, mycobacteria grow logarithmically, and blood-derived macrophages accumulate, but little tissue damage occurs. Two to three weeks after infection, T cell immunity develops, with antigen-specific T lymphocytes that arrive, proliferate within the early lesions or tubercles, and then activate macrophages to

kill the intracellular mycobacteria. Subsequent to this phase, the early logarithmic bacillary growth stops (**third stage**). Central solid necrosis in these primary lesions inhibits extracellular growth of mycobacteria. As a result, infection may become stationary or dormant. Disease may progress, and haematogenous dissemination may take place after primary infection (**fourth stage**), as well as months or years after wards (**post primary tuberculosis**), under conditions of failing immune surveillance. Liquefied caseous foci provide excellent conditions for extracellular growth of MTB. Cavity formation may lead to rupture of nearby bronchi, allowing the bacilli to spread through the airways to other parts of the lung and outside environment. In summary, after entry in the human lung, MTB has a series of encounters with different host mechanisms. The outcome of infection with MTB depends on the balance between (i) outgrowth and killing of MTB and (ii) the extent tissue necrosis, fibrosis and regeneration.

The ability to manipulate the immune system of mice with neutralizing antibodies or gene knockout (**KO**) has provided strong evidence that in this species, immunity to tuberculosis correlates with a Type 1 response. In vivo T-helper (**Th**) 1 or Th2 cells act in concert with CD8$^+$ T cells, and with numerous other cell types including macrophages, B cells and some stromal cells. Collectively these give rise to two patterns of cytokine release known as Type 1 (**dominated by interleukin-2 (IL-2), IL-12, and Interferon-γ (IFN-γ)**) and Type 2 (**dominated by IL-4, IL-5 and IL-13**) [18, 19]. The term "Type 1" is used preferentially to Th1 referring to the overall pattern of cytokine release by all cell types in the infected site. Disruption of the Major Hystocompatibility Complex (**MHC**) class II genes or of the gene for the b chain of the α/β T cell receptor [20] resulting in a deficiency of CD4$^+$ T cells, render mice susceptible

even to the avirulent Bacillus Calmette-Guerin (**BCG**). Disruption of the gene for the IFN-γ makes mice very susceptible to MTB (**death within 3 weeks**), and such mice may even die after many weeks from the challenge with BCG [21, 22, 23]. IL-18 KO mice are also more susceptible, perhaps because IL-18 contributes to the induction of IFN-γ expression [24]. A major inducer of Th1 pathway is IL-12. The exact role of IL-12 depends on the mouse strain [25], but IL-12 KO mice are not resistant to tuberculosis [26].

These data emphasize the crucial role of the Th1 immune response in tuberculosis immune response. In agreement with this, other data indicate that the Th2 immune response is not only unable to protect mice, but can seriously undermine the efficacy of the Th1 immunity. If a weak Th2 response to the shared mycobacterial antigens is deliberately induced before challenge, mice are found to be strikingly more susceptible to tuberculosis than non-immunized control animals [27]. Similarly, in the Balb/c mouse model of pulmonary tuberculosis, the appearance of IL-4 in the lung lesions coincides temporally and spatially with the appearance of areas of pneumonia and necrosis, leading to rapid clinical deterioration and death [28]. These observations are not contradicted by the claim that, in IL-4 gene disrupted mice; there is no evidence of increased resistance to the infection [29]. First, such mice are not devoid of Th2 cytokine activity because IL-13 can substitute for many functions of the KO mice. Secondly, the detrimental role of the Th2 response is most apparent in the late progressive phase of the disease, particularly after 60 days [27, 28].

Some confirmation of the need for Th1 responses in man as in mice emerged from comparisons of patients and healthy contacts. For instance, patients produce relatively more antibody, whereas normal contacts produce relatively stronger T cell response to the 30 kDa antigens of MTB. Moreover, the cells from patients release less IFN-γ and more IL-10 in the presence of the antigen [30]. Similarly, T cells from BCG-immunized

subjects respond more to the 16 kDa alpha-crystallin protein of MTB than do T cells from tuberculosis patients, who in contrast, have higher levels of antibody to it [31]. Findings of this type suggest that Th1 responses are protective in men, as in mice. The study of serum concentrations of cytokines is uninformative in tuberculosis [32].

In humans, the elimination of MTB infection manly depends on the success of the interaction between infected antigen presenting cells (**APCs**) and T lymphocytes. Primary as well as acquired immunodeficiencies, especially human immunodeficiency virus (**HIV**) infection, have dramatically shown the importance of cellular immunity in tuberculosis. CD4$^+$ T cells exert a protective effect by the production of cytokines primarily IFN-γ, after stimulation with mycobacterial antigens. The T cell response is mostly antigen specific, and attention has focused on the identification of immunodominant antigens, which may be used for the development of effective vaccine [33]. The acquired T cell response develops in the context of MHC complex and the polymorphism of MHC may contribute to differences in disease susceptibility of outcome [34, 35, 36].

Functional diversity of T lymphocytes may also be relevant. In addition to conventional CD4$^+$ T cells, several other T cell types are also involved in the response to mycobacteria and represented in the figure below. Experiments, involving adoptive transfer, in vitro cell depletion and gene KO, have illustrated the importance of CD8$^+$ T lymphocytes in the control of tuberculosis [37, 38]. Protection of mice vaccinated with mycobacterial heat shock proteins 65 deoxyribonucleic acid (DNA) appears to be mediated mainly by CD8$^+$ T cells [39]. In an in vitro system, this ability to activate CD8$^+$ T cells seemed to involve causing leakiness of the phagosome so that antigens reach the cytoplasm and hence join the conventional pathway for presentation on MHC class I [40,]

[41], though another novel pathway may also be involved [42]. A haemolysin-like molecule is in fact expressed by both MTB and BCG [43], and a BCG strain expressing the haemolysin from *Listeria monocytogenes* has been developed in the belief that this will increase the $CD8^+$ T cell response [44]. These $CD8^+$ T cells have been shown to be cytotoxic, though the mechanism of this cell killing has been controversial. It has been thought that most cytotoxic T cells act to lyse infected cells and allow the released mycobacteria to be taken up by activated, uninfected macrophages that may kill them. However, it now appears that some CTLs directly kill MTB via granule-associated protein, granulysin acting with perforin [45]. On the other hand, lysis by $CD4^+$ cytotoxic T cells does not reduce the viability of the contained bacteria [46]. Progression of tuberculosis in mice deficient in perforin is not different from progression in the wild type [47, 48]. The major role of murine $CD8^+$ T cells at this stage may be the secretion of IFN-γ [49]. Recently, tuberculosis-specific $CD8^+$ T cells have been identified in humans [50], but their role in this species is equally uncertain. There are $CD8^+$ T cells that will recognize tuberculosis-infected cells and secrete IFN-γ in blood from individuals with the disease [51], but these did not appear to contribute to control of intracellular proliferation of MTB in an in vitro system using human cells [52].

Phagolysosome fusion
Acidification
Iron restriction

RNI
S-nitrosothiols
dinitrosyl
iron complexes

Nitrogen
dioxide

ROI
Hydroxyl and
ferryl radicals

Hydrogen peroxide

Peroxynitrite

Nitric oxide

Superoxide

L-Arginine

Oxygen

Activated infected
macrophage

TNF-α

IFN-γ
CD4+
T-cell
LT-α3
apoptosis

IFN-γ
CD8+
T cell
Perforin
granulysin

IFN-γ
DN/
CD8+/CD4+
T cell
Perforin
granulysin

IFN-γ
γδ+
T cell
Perforin
granulysin

Perforin
Granulysin

Infected
macrophage

a Spontaneous
healing (?)

b Acute disease
(immunocompromised)

Containment (>90%)

c

Reactivation
(<10%)

Dissemination
transmission

Granuloma

Nature Reviews | Immunology

Most tuberculosis-specific CD8[+] T cells recognize their antigens in association with MHC class I, however some are now known restricted by other molecules such as CD1 system [53]. The relatively non-polymorphic CD1 family of molecules are MHC class I like, and possess cleft that binds lipid and glycolipid molecules [54] and allows their presentation to a variety of CD1-restricted cells, including αβ T lymphocytes negative for both CD4 and CD8 molecules (**double-negative T cells**), γδ T cells and certain CD4[+], CD8[+] and NK lymphocytes [55, 56]. The exact role of CD1 and CD1 restricted cells, in either protection or pathology of tuberculosis, have proven difficult to evaluate, because mice possess a homologue of CD1d but no homologues of human CD1a, b or c. Indeed, mice deficient in CD1d have not been found to differ in the control of tuberculosis [57], though there is one claim that neutralization of CD1 resulted in exacerbation of the infection in mice at very early time points. The relevance of these findings to human disease is doubtful. Human CD1d has not been shown to present mycobacterial antigens, unlike classical CD1a, b and c that may present mycolic acid, lipoarabinomannan and other cell wall components [58]. Double negative lymphocytes can recognize mycobacterial lipids in the context of CD1. Their predominant effector mechanism appears the secretion of IFN-γ and CD95/CD95L interactions [59, 60], and only rarely do they cause significant mycobacterial death. This has prompted suggestions that their role is the down regulation of local inflammatory responses by the removal of antigen-loaded antigen presenting cells. Many of the other types of human CD1-restricted cells also produce significant amounts of IFN-γ, but appear able to lyse infected cells and directly kill intracellular mycobacteria [61]. It appears that MTB may be able to down-regulate CD1 expression on human antigen presenting cells, thereby potentially evading this component of the immune response [62].

Th-2 immune response in human tuberculosis: detrimental role and its implication for vaccine design

The susceptibility of children with defective receptors for IFN-γ or IL-12 provides definitive evidence of the importance of Th1 cytokines, suggesting a close parallel with the mouse models. Recently, the negative role of Th2 cytokines in human tuberculosis, again paralleling the murine models, has been established [63]. Expression of IL-4, whether measured by flow-cytometry, or by sensitive quantitative RT-PCR on un-stimulated peripheral blood T cells, is increased and correlates with severity of diseases and with cavitation [64]. The IL-4 mRNA copy number also correlates with total immunoglobuline E (IgE). Thus although it is true that actual cytokine levels and mRNA copy numbers are higher for Th1 than Th2 cytokines in tuberculosis, the major change in cytokine expression compared to healthy donors is not as previously stated, the small decrease in expression of Th1 cytokines, but rather a massive increase in expression of Th2 cytokines. This has resolved a long-running controversy, which deserves explanation. That there is a Th2 component in the response of human tuberculosis patients to MTB ought to have been accepted 10 years ago, because there is no other known explanation for the presence of specific IgE antibody [65]. Interestingly, the other largely Type 2-cytokine dependent antibody, Immunoglobulin-G4 is also reported to be increased in patients [66]. Similarly, immunochemistry reveals IL-4 expressing cells in the lymphoid organs of tuberculosis patients [67]. Why then, has the matter been controversial? First, IL-4 is biological active at much lower concentrations than IFN-γ, and has a correspondingly lower mRNA copy number, so methods that reliably pick up IFN−γ or its mRNA fail to detect biologically significant levels of IL-4. Secondly, attempts to increase cytokine expression by stimulation of the cells in vitro do not yield an accurate reflection of the cytokine balance present in vivo, and rapid

early production of IFN-γ can suppress Th2 cytokine release. Finally, previous studies failed to take into account the presence of the IL-4 splice-variant. This variant of IL-4 may be an inhibitor of IL-4 activity, and is always co-expressed with IL-4, at about the same level [68]. In lung cells, it may be expressed at higher levels than IL-4 itself. However, almost every study of IL-4 mRNA levels used primers that would amplify mRNA for both IL-4 and the splice variant. It is possible that some of the relative deficit in IFN-γ expression and lymphoproliferation in the peripheral blood of tuberculosis patients is due to the sequestration of the antigen presenting cells in the lymphonodes [69] or site of disease [70]. However, this cannot fully explain the massive rise in expression of Th2 cytokines. What then, are the likely causes of this shift in cytokine profile? Increasing antigen load is likely to be one factor, since Th1/Th2 balance is strikingly linked to dose when immunizing with particulate antigens such as mycobacteria [71] or Leishmania [72]. In some populations, excessive or inappropriate contact with environmental mycobacteria may have primed a Type 2 response to the crucial antigens. This mechanism is clearly demonstrable in mice, in which it can massively increase the susceptibility, and has been suggested, but not conclusively proven in man [73]. During active tuberculosis, selective apoptosis of Th1 like T cells may be a factor, as may prostaglandin release and increased secretion of transforming growth factor-β (**TGF-β**) and IL-10 [74]. However, the latter may be a consequence of the shift towards a Th2 immune response. Finally, there are now strong reasons for suggesting that endocrine interactions with the immune system are important.

BCG and tuberculosis: controversies about an old vaccine

Ever since its introduction in infant immunization, Bacillus Calmette-Guerin or BCG vaccine has attracted more controversies than any other vaccine. A vaccine in general is adjudged on two important parameters: a) ability to protect individual from the particular disease and b) control of the disease at community level and possibly eliminate and eradicate the same.

BCG is now being used routinely in over 100 countries in their National Immunization Programme. The main objectives are to prevent disseminated and other manifestations of MTB. However, BCG does not prevent infection of MTB. Because of genetic changes in the bacterial strains that have occurred over many years, various BCG vaccines used throughout the world differ [75]. However, identification of complete BCG genome in 1998 has facilitated further research in development of more effective vaccine alternatives [76]. From the earlier observation of to 80 % efficacy, recent meta analysis have shown greater efficacy of > 80% against meningeal and miliary tuberculosis in children and in one meta analysis >50% efficacy was recorded even against pulmonary tuberculosis [75]. In short, endemicity of the disease, heavy bacillary load, constant contact with open tuberculosis case, concomitant HIV disease etc… are some of the factors which might affect the efficacy of BCG vaccine. In India, BCG vaccine is produced from Danish Strain 1331, based on the Copenhagen technology and standards. However, in the National Immunization Programme BCG vaccine produced from other strains are also supplied sometimes. Ever since the introduction of Universal Immunization programme in 1985, BCG vaccine, coverage has been uniformly stepped up to >85%. Sentinel centers under UIP have been constantly reporting low/nil incidence in meningeal tuberculosis, miliary tuberculosis and disseminated tuberculosis, which denote the field efficacy of BCG vaccine in controlling the haematogenous

spread of childhood tuberculosis. The identification of complete genome sequenced of MTB in 1998 has opened new vistas in developing newer anti-tubercular vaccines. Currently this research is mainly directed toward purification and synthesis of protein peptide and non-peptide antigens of MTB, creation of rationally attenuated mutant antigens from MTB, development of DNA vaccine based on published genome sequence, development of suitable vehicle for these potential subset vaccines using living vaccine carriers strain.

BCG is named after French scientists Calmette and Guerin who in 1908 isolated *Mycobacterium bovis* from a cow with tuberculosis mastitis. They cultured this isolate in a glycerinated, beef/bile/potato medium, subculturing every 3 weeks, until 13 years and 230 subcultures later, the bacillus had lost evidence of virulence [77]. After this acceptance, as a vaccine for tuberculosis in humans, the BCG Pasteur Lille was widely distributed throughout the world to other institutions. As a result, many daughter substrains come into being, and recent molecular analysis has revealed numerous changes, gene deletions, as well as a suspicion that continued passage has attenuated BCG to almost complete avirulence [78].

BCG vaccination is remarkably safe, unfortunately, although BCG has been effective in certain controlled clinical trials, in other, it has been disastrous, with no effect at all. An appreciation of this depends on a "glass half empty" or "half full". Certain a percentage of scientists falls into the half-empty group, believing that BCG is essentially worthless and needs to be completely replaced. Conversely, the half-full membership points to the fact that in some of the trials, BCG did work well indeed, whereas in other did not. So one question, still unanswered, is what is BCG doing when it does have positive effect?

In fact, the stark reality is that this question has never been adequately answered. If the working hypothesis is believed, that BCG induces memory immunity, but this immunity is gradually lost, then the literature shows that recent, serious studies of these parameters in models are counted on two hands. BCG can switch on a variety of mechanisms, as summarized in the figure below. Central to these is a potent, memory T cell response [79]. In areas in which BCG is not effective, one possible explanation is that this T cell memory pool is consumed or gradually influenced leading to a loss of efficacy. This may the result of non-specific stimulation of memory T cell turnover and division, which may force a percentage of the pool into apoptosis, thus eventually reducing the pool size to a frequency whereby it is no longer effective. However, all available evidence suggests that the BCG is insufficient. The exact reasons for this unsuccessful are not completely understood. Theories proposed include natural cross presentation or suppression resulting from exposure to environmental mycobacteria in tropical and temperate climates that may mask or impair the protective effect of BCG, co-infection with other pathogens such as helminths, as well as the genetic variability of vaccines [80]. Regardless of the explanation, it is generally agreed that a novel, more effective vaccine is required. Indeed, using mathematically modelling based on current global predictions; a new vaccine with only 50% efficacy could prevent 9 million deaths from tuberculosis by the year 2030. Of course, this level of protection would need to be achieved in many different populations, and not as a mere average of divergent groups. Therefore, it is critical that information concerning the host response to MTB and BCG is briefly reviewed when considering new potential vaccine candidates.

In particular, the primary habitats of mycobacteria are the macrophages and dendritic cells and all problems concerning the trigger of the effective immune response by these APCs will help to design a novel anti-mycobacterial vaccine.

Influence of environmental mycobacteria on BCG vaccination in tropical areas

The reason of BCG failure in some populations has been subject of debate since the 1950s, and many different hypotheses have been suggested to explain the observed variation. Some investigators have suggested that difference in the strain of BCG, the age of vaccination, or methodological differences are important factors for the variation reported. The most widely accepted hypothesis relates the efficacy of BCG to geographic location, with low to non-detectable levels of protection against tuberculosis seen in tropical regions such as Africa and India, where exposure to nontuberculous

mycobacteria is common [81]. One exception from this general role is the consistent high efficacy when BCG is used to vaccinate newborn. Neonatal vaccination with BCG imparts protection against childhood manifestations of tuberculosis (**in particular meningitis**) [82], but the efficacy wanes over a period of 10 to 15 years, and therefore it does not prevent pulmonary tuberculosis in the adult population in the third world. There is convincing evidence that exposure of laboratory animals to environmental mycobacteria can provide some protection against infection of MTB [83]. The prior sensitization with environmental mycobacteria can inhibit BCG multiplication and thereby prevent the induction of an efficient BCG-mediated immune response and protection against tuberculosis [80, 84]. This can be explained through the particular sensitivity of BCG to the influence of pre-existing immune response to antigens shared between environmental mycobacteria and BCG. The multiplication of BCG is a precondition for the induction of immunity by BCG and killing of BCG by chemotherapy after administration has been demonstrated to abrogate subsequent immunity completely. This inhibitory effect provides an important argument in the ongoing discussion of live attenuated vaccines versus nonviable subunit vaccines against tuberculosis.

Role of Dendritic Cells in tuberculosis infection and BCG vaccination

It is well established that Dendritic cells (DCs) are APCs specialized for naïve T cell activation [85]. Immature DCs are bone marrow-derived cells present in most non-lymphoid tissues, where they act as sentinel cells against incoming pathogens. DCs are characterized by a high capability for antigen capture and processing, but low T cell stimulatory activity. Inflammatory factors or microbial component, promote DCs maturation and migration out of the non-lymphoid tissues into the blood or afferent lymph. Maturing DCs then will rich lymphoid organs, where they home to T cell areas. At this stage, DCs have undergone a dramatic change in their properties, having lost the ability to capture antigens but having acquired an increased capacity to prime T cells [86, 87]. The summary of the dendritic cell-life is shown in the figure below.

This unique capacity of DCs to sample antigens at the site of infection, respond to microbial signals and activate naïve T cells suggests that they play a critical role in the initiation of antimicrobial immunity. Although DCs are efficient APC, it is also

apparent that they act as key modulators of immune response. The innate response of DCs to microbial antigens may preferentially drive CD4[+] T cells to mature into Th1 or Th2 cell types, therefore controlling the generation of Th1 or Th2 immune responses to the pathogens [88]. This immune activity has been clearly demonstrated in experiments involving the intravenous injection of mice with an extract of *Toxoplasma gondii* [89]. After 3 hours, IL-12 production was detected in the spleen of animals. The IL-12 producing cells were identified as DCs localized in the T cell areas of the spleen. This IL-12 production was independent on T cell signals, thus demonstrating that DCs were the initial source of IL-12 in response to microbial stimulus. This IL-12 producing feature of DCs is of particular relevance in mycobacterial infections, since the production of IL-12 in response to MTB is a key event of protective immunity. The function of IL-12 is to activate naïve T cells and NK cells, as well as directing CD4[+] T cells down the IFN-γ secreting pathway. In this way, IL-12 serves as a bridge between innate resistance and adaptive immune response against intracellular pathogens. The stimulation of IL-12 production by DCs in response to mycobacterial antigens may lead to accelerated Th1-oriented immunity and therefore to a better control of the disease. Research into the impact of mycobacterial infection on DCs has been facilitated by the development of culture conditions in which immature DCs of murine or human origin van be grown from precursors in the presence of growth factors [90, 91]. DCs can internalize mycobacteria, either heat-killed or alive, with equal efficacy. Such phagosytosis may be enhanced by specific interactions between the bacilli and DCs surface molecules. Interaction of DCs with live MTB or BCG results in a direct cell maturation documented in DCs phenotype and in cytokine production and chemokines expression. Mycobacteria-infected DCs have a decreased endocytic activity, as shown by their low capacity to internalize latex beads or dextran after the infection [92].

Similarly to other bacterial products, such as LPS, mycobacterial stimuli up-regulate the DCs expression of co-stimulatory molecules such as CD80, CD86, the intercellular adhesion molecules (ICAM-1) and the signalling molecules CD40 [93]. MTB or BCG infection of DCs also up-regulate the expression of MHC molecules, suggesting that infected DCs have an increased capacity to stimulate T cells against mycobacterial antigens. Accordingly, BCG-infected DCs are more efficient than un-infected DCs at eliciting specific cellular responses *in vivo* [94].

In addition to the classical MHC system, DCs can present non-protein antigens to T cells by CD1 molecules. The impact of mycobacterial infection on CD1 expression is not clear, since MTB infection has no effect on CD1a, b, c expression on human PBL derived DCs [92]. The presence of CD1$^+$ DCs in human leprosy lesions correlates directly with effective immunity, suggest that CD1 presentation of antigens may play a role in augmenting host defence against mycobacterial infection [95]. Indeed, the major mycobacterial cell wall component lipoarabinomannan (LAM) is presented by CD1b. similarly CD1a and CD1c have been found to present mycobacterial lipids to human T cells [56]. Because CD1 expression is down regulated in MTB infected macrophages, it is tempting to postulate that MTB may have developed evasion mechanisms to escape mycobacterial antigens presentation through CD1 molecules [62]. Mycobacterial infection of DCs results in the up-regulation of the regulatory cytokines such as IL-12 and TNF-α. These molecules play a major role in protective immunity against MTB infection, because they contribute to the acquired specific resistance and to the development of delayed-type hypersensitivity (DTH) [96]. The IL-12 production induced by mycobacterial infections potentiates the development of T cells that produce IFN-γ and TNF-α, both potent activators of bacterial killing by infected macrophages [97]. The

generation of IL-1β, IL-6 and TNF-α contribute to the development of the inflammatory process, through the recruitment of leukocytes leading the granuloma formation and the containment of bacterial dissemination [98]. Interestingly, these pro-inflammatory molecules are secreted in greater quantities from DCs cultured with live bacilli than with killed bacteria [92]. This feature may explain the lack of efficacy of killed BCG compared to live BCG as a vaccine against MTB infection [33]. DCs infection with MTB also induces the early production of IL-10 [92]. Because IL-10 is a potent suppressor of macrophages effector functions, this interaction between lung DCs and mycobacteria may result in local inhibition of the resident macrophages activation and alter the ensuing bacterial clearance. It has been demonstrated that IL-10 may inhibit the development of cellular responses to mycobacteria suppressing the release of IL-12 by DC [99]. IL-12 production by BCG-infected DCs is significantly higher in IL-10 deficient cells and this effect is reinforced on CD40 ligation. This allows that IL-10 exerts an inhibitory effect on both mycobacteria and CD40 induced IL-12 production by DCs. These data are in accordance with previous studies showing that the addition of exogenous IL-10 to LPS-activated monocytes and LPS or CD40-activated DCs blocks their IL-12 synthesis. This blocking effect is likely to have a marked effect on the generation of protective immunity in vivo, because it would inhibit both innate and adaptive IL-12 responses of DCs to mycobacteria and may account for the increased antimycobacterial immunity of IL-10 deficient mice in response to BCG infection [100]. The generation of proinflammatory cytokines is an essential component of resistance against tuberculosis infection. The production of chemokines at the site if infection is also an important element of the immune response to mycobacteria, because it controls the further recruitment of DCs precursors and the influx of cells participating to the inflammation process [101]. These cells include monocytes that are the direct precursors of

DCs and activated lymphocytes, which contribute to granulomas formation. Summarizing these observations, mycobacterial infection of DCs induces cell maturation and up-regulation of the production of inflammatory cytokines and chemokines that are essential for the resolution of mycobacterial infections. Importantly, mycobacteria-infected DCs express high levels of IL-12 and the production is enhanced by CD40 stimulation, a fact that may contribute to the generation of the Th1 immune response. In this context, it is important also the contribution of IL-10 developed early in infection that can be a mechanism for mycobacteria to escape immunity down modulating the pre-existent Th1 immune response. In the figure below, the representative panel of the DCs function in mycobacterial infection is shown.

Aims of this study

Peripheral blood monocytes can differentiate into dendritic cells or macrophages depending on environmental factors encountered during their migration from blood to peripheral tissues [102, 103]. Transendothelial trafficking and culture in the presence of serum from systemic lupus erythematous induce monocyte differentiation into immature DCs [104]. Upon contact with IL-4 plus GM-CSF (**cytokines that could be produced by tissue mast cells**), monocytes also differentiate into immature DCs. Addition of TGF-β or exposition of monocytes to GM-CSF plus IL-15 lead to DCs features of Langherans cells. In contrast, M-CSF is a potent macrophage differentiation factor. IL-6 also shifts monocyte differentiation from DCs to macrophages. Tumor cells produce IL-6 and M-CSF that shift the differentiation of $CD34^+$ progenitors from DCs to macrophages [105]. In addition, cytokines such as IFÑγ produced by NK cells or activated T cells can modify the pattern of differentiation of DCs.

At the sites of inflammation, cytokines and chemokines promote the activation of resident DCs and the recruitment of DCs precursors. Dendritic cell precursors may permeate peripheral tissues including the skin, where they receive stimuli from local infection or inflammation [106]. Different signals of infection, inflammatory cytokines such as TNF-α or phagocytosis have been demonstrated to interfere with DCs differentiation [107, 108]. Many pathogens have evolved mechanisms to exploit DC biology in their dissemination within the body, and/or interfere with DC functions to block or delay their elimination by the host. Several pathogens or their components can interact with either imDCs or their precursors influencing DC generation [109, 110]. It has been demonstrated that MTB, is able to subvert the differentiation of infected monocytes into DCs, generating a subset of DCs population unable to induce an effective immune response and suggesting an escape mechanism which contribute to mycobacterial

intracellular persistence [111]. Several properties of MTB are retained by BCG and other mycobacteria that can explain one of the mechanisms of the failure of vaccination and the influence of the habitat in the immune response to MTB. Indeed, the unsuccessful of tuberculosis vaccination may be at least partially explained by the induction of poor or inappropriate host responses induced by APCs.

Because of the role of DCs in the induction of immune response to *M. tuberculosis* and the contribution to the generation of protective cellular immunity against mycobacteria during the vaccination with BCG, we hypothesized that BCG can retain the capacity to influence DCs functions. In this work, we investigated the effects of BCG comparing to that of environmental mycobacteria on the differentiation of monocytes into imDCs and mDCs to obtain findings explaining some mechanisms underling the failure of the BCG vaccine to prevent pulmonary tuberculosis.

2. Experimental procedures

Mycobacteria

In all experiments, Bacillus Calmette Guerin or BCG vaccine from Aventis Pasteur (Paris, France) has been used. Lyophilized BCG was resuspended in physiologic solution at approximately 1 x 10^6 Colony Forming Units (CFU) per 100 μl.

Mycobacterium smegmatis (**Msm**) MC^2 155 strain has been used. Mycobacteria were grown in Middlebrook 7H9 medium for 3-4 days and frozen stocks were stored at -80 °C in medium and glycerol 15%. In some experiments, mycobacteria were inactivated by incubating them for 60 minutes at 80°C. The viability of bacteria was assessed by Colony Forming Units (**CFU**) analysis.

Monocytes purification, infection and DCs generation

Peripheral Blood Mononuclear Cells (**PBMCs**) were isolated from buffy-coats of healthy donors by density gradient centrifugation using Lympholyte-H (Cederlane, Canada). Monocytes were positively separated by anti-CD14 magnetic beads (MACS, Milteny Biothec, Germany) according to the manufacturer's instructions. The cells were then resuspended in RPMI 1640 (Euroclone, UK) supplemented with 10% FCS (Biowittaker, Belgium), L-glutamine (2mM), Hepes buffer (10mM), sodium piruvate (0.1 M), non-essential amminoacids (0.1 M) (Euroclone, UK) and gentamycin (10μg/ml) (Sigma-Aldrich, Germany). Monocytes were infected for three hours with single cell suspensions of BCG at a multiplicity of infection (MOI) of 1, or stimulated with LPS (from *E. coli*, 1μg/ml) (Sigma-Aldrich, Germany). The infection was carried out in the absence of antibiotics. After the treatment, monocytes were washed and cultured with fresh complete medium for 5 days in the presence of granulocytes-

macrophages colony-stimulating factor (GM-CSF) (200 U/ml) and interleukin-4 (IL-4) (10ng/ml) (Euroclone, UK) to generate imDCs. To induce final maturation of imDCs, LPS (200ng/ml) was added at the fifth day of culture for further two days. Viability of infected cells was determined by trypan-blue exclusion.

Fluorochrome-Activated Cell Sorter (FACS) analysis

The following FITC- or PE-conjugated antibodies: anti-HLA class I, HLA DR, CD1a, CD11c, CD14, CD40, CD64, CD80, CD83, CD86, CCR7 (Becton Dickinson Bioscience Mountain View, CA, USA), were used for direct immunofluorescence staining to characterize the phenotype of DCs generated in different conditions. Briefly, the cells were washed twice in PBS, 1% BSA and 0.1% sodium azide and stained with the mAbs for 15 min at 4°C. The cells were then washed and acquired using a FACScalibur instrument running Cellquest Software (Becton Dickinson).

Confocal Laser-Scanning Microscopy (CLSM) analyses

For CLSM analyses, $5x10^5$ DCs were added per well in a U-bottom microtiter plate and washed once with PBS containing 0.2 mM NaN_3 and 1% BSA. Cells were incubated (30 min., +4°C) with appropriate dilution of anti-CD1a-FITC or anti-actin-PE mAbs. After extensive washes, the cells were fixed with 3% paraformaldehyde, washed once and mounted on the microscope slide with the Prolong antifade reagent (Molecular Probes). The control samples were treated in the same way. For intracellular staining, the cells were fixed and permeabilized with cold methanol (-20°C, 10 min.) and then incubated with the antibody for 30 min. at 37°C.

CLSM observations were done using a Leica TCS 4D apparatus, equipped with an Argon-Krypton laser, dichroic splitter (488 nm), 520-nm long-pass filter for

observations with FITC-conjugated antibody. Image acquisition and processing were conducted by using the Scanware (Leica Lasertechnik GmbH, Heidelberg, Germany) and Adobe Photoshop software programs.

Transwell experiments

In transwell experiments, the infected and uninfected monocytes were separated by a membrane (6.5 mm of diameter, 0.4 μm pore size) in 24-well plates (Corning-Costar, Cambridge, MA). The lower compartment of the wells contained untreated monocytes (1×10^6 cells). The upper compartments contained either untreated cells, BCG-infected or LPS-treated monocytes (1×10^6 cells). The cells were cultured in the presence of GM-CSF and IL-4 in 2 ml of culture medium. After five days, the cells were harvested from the lower and upper compartments, stained with the anti-CD1a mAb and analyzed for the CD1a expression by FACS.

Cytokine assay

Supernatants of DCs derived from treated or untreated precursors were collected at the fifth day of culture or after stimulation with LPS (200ng/ml) for 48 hours and stored at – 80°C. The levels of IL-10, IL-12, TNF-α, IL-1β and IL-6 were determined by ELISA kits (Pierce, Endogen, USA), according to the manufacturer's instructions. Supernatants of CBMCs and purified $CD4^+CD45RA^+$ T cells co-cultured with DCs generated from untreated, BCG-infected or LPS-treated monocytes were tested for IL-4 and IFN-γ using commercially available ELISA kits (Pierce, Endogen, USA). Results are expressed as pg/ml. In some experiments, supernatanants of DCs co-cultured with naive T cells from cord-blood were tested for IL-2, IL-4, IFN-γ, TNF-α using

commercially available Cytokines Beads Assay (CBA) kit (Becton Dickinson Bioscience, Mountain View, CA, USA). Results are expressed as pg/ml.

T lymphocyte proliferation and functional polarization

DCs derived from untreated, BCG- or *Msm*-infected monocytes (0 to 1 x 10^4 cells) were added to 5 x 10^4 allogeneic PBMCs in 96 well U-bottom microplates (Corning-Costar, Cambridge, MA). The proliferative response was measured after 5 days of culture and 16 hours of incubation with {^{3}H}thymidine (Amercharm, Little Chalfont, GB) (1µCi/well). Incorporated radioactivity was then assessed by a 1450 MicroBeta Trilux (Wallac, Turku, Finland). Results are expressed as means $\pm$ SD of triplicate wells. T lymphocyte polarization was evaluated incubating DCs with Cord-Blood Mononuclear Cells (**CBMCs**) and purified CD4$^+$CD45RA$^+$ T cells at ratio of 1:5 for 8 days. CD4$^+$CD45RA$^+$ T cells were purified by incubating CBMCs with anti-CD45RA magnetic beads (MACS Milteny Biothec, Germany). According to the manufacturer's instruction, after O/N incubation to allow beads degradation, CD4$^+$ T cells were further purified. Supernatants were collected and analyzed for cytokine accumulation.

Statistical analysis

Statistical analysis was determined using a Student's *t* test. Values of $p < 0.05$ were considered statistically significant.

3. Results

Phenotypic characterization of DCs derived from BCG-infected precursors

In order to investigate the effect of BCG in DCs differentiation from peripheral monocyte precursors, we purified human monocytes from buffy-coats of healthy donors and infected with BCG at MOI of 1 for three hours. On attempt to evaluate the efficiency of BCG infection of human monocytes at MOI of 1 after 3 hours of incubation, we labelled BCG with FITC (**1μg/ml**) by incubating the bacteria for 30 min at 4° C and then washed extensively. Labeled bacteria were used for the infection and after 3 hours of incubation, monocytes were washed 3 times with fresh medium and analyzed by FACS. More than 90 % of the cells were FITC positive, suggesting the percentage of infected cells. (**Figure 1**)


Figure 1. Purified monocytes (98%) were infected with BCG FITC labelled at MOI of 1 for three hours. After the infection, monocytes were washed 3 times in PBS and analyzed by FACS. Dot plots show the percentage of positive cells

We cultured infected monocytes in complete medium containing GM-CSF and IL-4 for five days. Human monocytes developed into imDCs characterized by the acquisition

of CD1a and the loss of CD14 and CD64 molecules. ImDCs can be induced to maturation by several stimuli, including LPS. The maturation process is associated with the expression of CD83 and CCR7 and a strong up-regulation of CD40, CD80, CD86 and MHC class I and II molecules. In contrast, imDCs generated from BCG-infected monocytes (**BCG-DCs**) did not express CD1a on their surfaces (**Figure 2**).

Figure 2. BCG-infected monocytes differentiate into mature DCs with a failure of CD1a expression. Histogram plots show the phenotype of DCs derived from BCG-infected (BCG-DCs) or untreated monocytes (imDCs) at the fifth day of culture (filled histogram) and after 48 hours of LPS stimulation (empty histogram). The cells were stained for the various markers and acquired by FACScalibur. Numbers indicate mean fluorescence intensity values at fifth day of culture (bold) and after LPS stimulation (normal). One representative result of ten independent experiments is shown.

However, BCG-DCs were CD14$^-$ and CD64$^-$ (**data not shown**), suggesting that they were not blocked at the monocyte/macrophage stage. Furthermore, BCG-DCs at the fifth day of culture, expressed higher levels of MHC class I, class II and CD80, CD86 co-stimulatory molecules than imDCs in the absence of maturation stimuli. Interestingly, BCG-DCs acquired the phenotype of mDCs at the fifth day of culture, as shown by the expression of the maturation markers such as CD83 and CCR7 (**Figure 3**). The presence of CCR7 suggests that the infection is sufficient to induce migratory receptor expression required by mDCs to reach lymphoid organs. Following stimulation with LPS (**200ng/ml**) for 48 hours, BCG-DCs did not further up-regulate their maturation markers. Moreover, imDCs after stimulation with LPS acquired a mature phenotype, showing the increase of MHC class I, class II, CD80 and CD86 and the induction of CD83 and CCR7.

Together with these data we wondered whether the acquisition of early mature phenotype by DCs was due to simply stimulation of monocytes with bacterial products. We used LPS to stimulate monocytes before culturing them for five days in the presence of GM-CSF and IL-4. After five days we compared the DCs generated by LPS treated monocytes (**LPS-DCs**) and DCs generated by BCG infection. In contrast to BCG-DCs, the phenotype of LPS-DCs was similar to that of imDCs except for the expression of MHC class II which was up-regulated and the CD1a expression that shows the slight reduction (**Figure 3**). After the stimulation for further 48 hours with LPS, LPS-DCs acquired the mature phenotype, showing the increase of MHC class I, class II, CD80 and CD86 and the new acquisition of CD83 and CCR7.

Figure 3. LPS-stimulated monocytes differentiate into DCs with a similar phenotype of imDCs derived from untreated monocytes, except for MHC class II.

All these effects were observed using monocytes isolated from different donors and each experiment was reproducible (**Figure 4**).

Figure 4. Histograms show the mean of MFI (Mean Fluorescence Intensity) of ten independent experiments. Black bars indicate the MFI at fifth day of culture and white bars indicate the MFI after further 48 hours of LPS stimulation.

Furthermore, the incubation of monocytes that had phagocytosed heat killed BCG developed into DC (**hkBCG-DCs**) displaying a phenotype resembling that of BCG-DCs showing a strong up-regulation of CD86. However, CD1a expression was not completely negative and other markers such as MHC class I, class II and CD80 were less up-regulated indicating a low degree of maturation in comparison to BCG-DCs (**Figure 5**).

Figure 5. Histogram plots of a representative experiment of monocytes infected with heat killed BCG and cultured with GM-CSF and IL-4 for five days. Numbers indicate the MFI

Finally, the peculiar phenotype of BCG-DCs is dependent of mutiplicity of infection and the maximum effect was observed at MOI of 1. Higher multiplicity of infections resulted in a high mortality of monocytes and in no further variation of surviving cells (**data not shown**)

Distribution of CD1a molecules in BCG-DCs

It has been described that DCs with the CD1a$^-$ phenotype generated in different experimental conditions, have the capacity to produce IL-10 and to polarize T cells towards a Th2 response [112, 113]. On the other hand, it has been reported that mycobacterial infections interfere with the surface expression of CD1 molecules and that mycobacterial antigens interact with different members of CD1 family [62]. To investigate whether BCG-DCs are a subset derived from distinct precursors giving rise to CD1a$^-$ DCs population, or whether the down modulation of CD1a is induced by the infection, we analyzed the distribution of CD1a by confocal microscopy. The cells were analyzed by dual immunofluorescence staining using confocal laser-scanning microscopy analyses at the fifth day of culture. Immature DCs and BCG-DCs were fixed with cold methanol and labeled with anti-CD1a-FITC-conjugated and anti-actin-PE-conjugated mAbs for the intracellular staining. As demonstrated by merging the CD1a and Actin staining, BCG-DCs did not express the CD1a molecules on the surface, but CD1a molecules were present in intracellular compartment (**Figure 6**). This suggests that BCG induces a down modulation of CD1a, interfering with the differentiation of monocytes into DCs and not inducing the selection of a distinct DCs subset.

Martino A. et al. Journal of Leukocyte Biology, 190:1167-1176, 2004

Figure 6. Confocal laser-scanning microscopy (CLSM) analyses of localization of CD1a molecules in DCs derived from untreated (imDCs) or BCG-infected (BCG-DCs) monocytes. BCG-DCs and imDCs were fixed and permeabilized with cold methanol (-20°C, 10 min.) and then incubated with the appropriate dilution of the anti-CD1a-FITC (green) and anti-actin-PE (red) mAbs for 30 min at 37°C. image acquisition and processing were conducted by using the Scanware and Adobe Photoshop software programs.

Environmental *Mycobacterium smegmatis* affects DCs differentiation

In order to investigate whether the infection of monocytes with a different mycobacterium had the same influence on DCs differentiation, we infected monocytes with an environmental non pathogenic *Mycobacterium smegmatis* at the same MOI of infection for three hours and we evaluated the capacity to differentiate into competent DCs. DCs generated in the presence of live *Msm* (***Msm*-DCs**) did not express CD1a on their surface (**figure 7**) and were CD14 and CD64 negative, suggesting that environmental mycobacteria have the same capacity of BCG to interfere with DCs differentiation phenotype. Moreover, their viability was not affected by the infection (**data not shown**). On the other hand CD1a molecules on the *Msm*-DCs derived from heat-killed *Msm*-infected monocytes (**hk*Msm*-DCs**) was not completely down-modulated. *Msm*-DCs derived from live or dead *Msm*-infected monocytes both up-regulate MHC class I, class II and CD80, CD86, compared to imDCs after five days of culture. They differentiated directly into mature DCs expressing CD83, CD25 and CCR7 acquiring the mature phenotype in the absence of maturation stimuli. Upon 48 hours stimulation with LPS, also *Msm*-DCs did not further up-regulate the expression of maturation molecules, suggesting that they acquired directly a fully mature phenotype.

Figure 7. *Msm*-infected monocytes differentiate directly into mature DCs. Histogram plots show the phenotype of DCs derived from untreated (imDCs), live (*Msm*-DCs) or heat killed (hk*Msm*-DCs) *Msm*-infected monocytes at fifth day of culture with GM-CSF and IL-4. Histogram plots of DCs derived from untreated monocytes and stimulated for further 48 hours with LPS are shown (mDCs). Cellular phenotype was analyzed by FACS and the numbers indicate mean fluorescence intensity values. One representative of seven independent experiments is shown.

The acquisition of mature phenotype is independent on TNF-α

It has been described that TNF-α treated monocytes differentiate into partially mature DCs [107]. Since mycobacteria infected monocytes induce the production of TNF-α and avirulent mycobacteria induce higher amounts of TNF–α than virulent mycobacteria [114], we tested whether the TNF-α produced following infection of monocytes was related to the acquisition of mature phenotype of DCs. The cells were infected with *Msm* at MOI of 1, washed and cultured for 5 hours in the presence of brefeldin A to block the exocytosis and the production of TNF-α was evaluated by

intracellular staining. We found that about 49% of infected monocytes produced high levels of TNF–α (**Figure 8, A**). To investigate whether the high amount of TNF-α produced by *Msm*-infected monocytes was involved in the induction of early mature phenotype observed in *Msm*-DCs, we performed experiments in the presence of neutralizing anti-TNF-α mAbs. We found that the phenotype of *Msm*-DCs differentiated in the presence of neutralizing anti-TNF–α mAbs was comparable to that of *Msm*-DCs (**Figure 8, B**), suggesting that additional factors than TNF-α are involved in the induction of early mature phenotype of DCs generated from *Msm*-infected monocytes.


Figure 8. The induction of mature phenotype of *Msm*-DCs is independent on TNF-α. A) Purified human monocytes were infected with *Msm* at MOI of 1 for three hours and then washed extensively. Then they were cultured for 5 hours in the presence of Brefeldin A to block the exocytosis and stained with anti-CD14 and anti-TNF-α . The percentage of TNF-α positive cells is shown. B) purified human monocytes were cultured in the presence or absence of blocking monoclonal anti TNF-α for 5 days and in the presence of GM-CSF and IL-4 to generate DCs. One representative of three independent experiments is shown.

The induction of early mature phenotype requires mycobacteria-monocytes interaction

To investigate whether the generation of BCG-DC or *Msm*-DCs was due to the interaction of mycobacteria with monocytes or to soluble factors produced upon mycobacterial infection, we performed a set of transwell experiments. The untreated monocytes were cultured in the lower chambers and either untreated, *Msm*- or BCG-infected monocytes were placed into the upper chambers in the presence of GM-CSF and IL-4 for five days. The expression CD1a, CD83 and CCR7 of the resulting DCs populations both in the lower and upper chambers was analyzed by FACS. DCs derived from monocytes cultured in the lower chamber were CD1a$^+$ in all culture conditions, and showed the phenotype of imDCs, they were CD83 and CCR7 negative (**Figure 9, panel A**) whereas BCG-DCs and *Msm*-DCs did not express CD1a and acquire CD83 and CCR7 as above described. In the panel B, the result regarding the CD1a expression (**MFI**) as mean $\pm$ SD of 3 independent experiments is shown. This result suggests that the CD1a$^-$ phenotype of BCG-DCs and *Msm*-DCs requires the interaction of monocytes with mycobacteria and is not due to a soluble factor produced by infected cells.

Figure 9. Mycobacteria-monocyte interaction is necessary to generate *Msm*-DCs and BCG-DCs. Mycobacteria-infected and uninfected monocytes were separated by a membrane (6.5 mm of diameter, 0.4 ∝m pore size) in 24-well plates (Costar, Cambridge, MA). The lower compartments of the wells contained untreated monocytes (1 x 10[6] cells). The upper chambers contained either untreated or Mycobacteria--infected monocytes (1 x 10[6] cells). The cells were cultured in the presence of GM-CSF and IL-4 in 2 ml of culture medium. After five days, imDCs were harvested from the lower chamber and analyzed by FACS staining for the CD1a, CD83 and CCR7 expression. One representative of three independent experiments is shown (panel A.). The result regarding the CD1a expression (MFI) as mean $\pm$ SD of 3 independent experiments is shown in the panel B.

T cell stimulation by BCG-DCs

To test whether the differentiation of infected precursors into BCG-DCs induces an alteration of their antigen presenting capacities, imDCs, DCs derived from BCG infected or LPS treated precursors were co-cultured with allogeneic PBMCs isolated from healthy donors at various DC: T cell ratios either before or after induction of maturation in the presence of LPS (**Figure 10**). Although BCG-DCs showed at the fifth day of culture the up-regulation of MHC class I, class II, CD80 and CD86 molecules, they were not more efficient to stimulate allogeneic PBMCs comparing to imDCs and LPS-DCs. However, upon further maturation stimuli, BCG-DCs increased their antigen presenting capacity as well as imDCs and LPS-DCs, suggesting that they are able to acquire the functions of fully mature DCs.

Martino A. et al. Journal of Leukocyte Biology, 190:1167-1176, 2004

Figure 10. Antigen presenting capacity of DCs derived from untreated (imDCs), BCG-infected (BCG-DCs) or LPS-treated (LPS-DCs) monocytes. The cells cultured in the presence of GM-CSF and IL-4 for five days (empty symbols) or induced to maturate in the presence of LPS (filled symbols), were co-cultured with allogeneic peripheral blood T lymphocytes. After 5 days, T cell proliferation was assessed by the addition of tritiated thymidine for 16 h. Results of 2 experiments are expressed as mean counts per minute (CPM) of triplicate cultures.

T cell stimulation by *Msm*-DCs

In the same manner, we tested whether the acquisition of mature phenotype by *Msm*-DCs resulted in an increased capacity of *Msm*-DC to stimulate T cell response, imDCs, mDCs (**imDCs + LPS**), and DCs derived from *Msm*-infected-precursors, were co-cultured with PBMCs isolated from healthy donors at various DC:T cell ratios and 3H-thymidine incorporation was measured. Consisting with the early mature phenotype acquired from DCs generated from *Msm*-infected monocytes, we found that *Msm*-DCs showed higher capacities to stimulate allogeneic T cells compared to mDCs and even more compared to imDCs (**Figure 11**).

Figure 11. *Msm*-DCs induce a strong proliferation of allogeneic PBMC. ImDCs, *Msm*-DCs or DCs stimulated for 48 hours with LPS (mDCs) were used to stimulate allogeneic PBMC. After 6 days of culture T cell proliferation was assessed by the addition of tritiated thymidine for 16 h. Results are expressed as mean counts per minute (CPM) of triplicate cultures

Pro-inflammatory cytokines production by BCG-DCs

The secretion of pro-inflammatory cytokines by DCs, such as TNF-α, IL-1β, and IL-6 in imDCs, BCG-DCs and LPS-DCs was evaluated at the fifth day of culture by ELISA. Uninfected DCs were not able to produce TNF-α and IL-1β cytokines but only low amounts of IL-6 in the absence of maturation stimuli (**Figure 12**). Similar results were obtained by DCs generated from LPS-treated monocytes, although they secreted high levels of IL-6. In contrast, BCG-DCs produced high levels of TNF-α, IL-1β and IL-6, showing that they have acquired an activated phenotype.

Martino A. et al. Journal of Leukocyte Biology, 190:1167-1176, 2004

Figure 12. Pro-inflammatory cytokines secretion by DCs derived from untreated (imDCs), LPS treated monocytes and BCG-infected (BCG-DCs) monocytes. Cell supernatants were collected at the fifth day of culture and tested for TNF-α, IL-1β and IL-6 by ELISA. Results are expressed as means ($\pm$SD) of six different experiments and statistical analysis was determined by non parametric t test. The significant levels between BCG-DCs and compared to imDCs were p<0.05.

Immunoregulatory cytokines production by BCG-DCs and *Msm*-DCs

Furthermore, the accumulation of IL-10 and IL-12, which are important factors involved in directing immune response, was measured either at the fifth day of culture or after LPS stimulation in BCG-DCs and LPS-DCs cultures. In the absence of maturation stimuli, imDCs did not produce IL-12 or IL-10 and after LPS stimulation the production of IL-12 was induced as previously reported [92] (**Figure 13**). On the other hand, DCs generated from LPS-treated monocytes secreted high amounts of IL-12 and low levels of IL-10 at the fifth day of culture and after maturation stimuli. In contrast, BCG-DCs produced high levels of IL-10 and were not able to produce IL-12 either before or after LPS stimulation. These data indicate that BCG-infected monocytes are able to differentiate into DCs that produce pro-inflammatory cytokines and IL-10 either at five days of culture or upon maturation stimuli.

Figure 13. DCs derived from BCG-infected monocytes (BCG-DCs) produce high levels of IL-10. Cell culture supernatants were collected from untreated DCs (imDCs), BCG-DCs and DCs derived from LPS-treated monocytes (LPS-DCs), either at the fifth day (A) or after further 48 hours of LPS stimulation (B). IL-10 and IL-12 were tested by ELISA. Data are expressed as means ($\pm$ SD) of six different experiments and statistical analysis was determined by non parametric t test. The significant levels (*) between BCG-DCs compared to imDCs were p<0.05.

The production of immunoregulatory cytokines IL-12 and IL-10 was valuated in *Msm*-DCs to test if non pathogenic environmental mycobacteria are able to modify the cytokine pattern of DCs. In different experiments, we collected culture supernatants before and after LPS stimulation. In the absence of maturation stimuli, *Msm*-DCs did not produce IL-12 and the production of IL-10 was slightly induced (**Figure 14**). However, upon LPS stimulation the imDCs produced high levels of IL-12 (**p70**) and low IL-10 as expected, and the DCs generated from *Msm*-infected, produced high levels of IL-10 and retained also the capacity to produce significantly high amounts of IL-12. These data

indicate that *Msm*-infected monocytes are able to differentiate into DCs producing both

IL-12 and IL-10, which balance could play a role in the T cell immune response.

Figure 14. IL-12 (p70) and IL-10 production by *Msm*-DCs. The supernatants of imDCs and *Msm*-DCs were collected at fifth day of culture and after 48 hours in the presence of LPS (imDCs+LPS and *Msm*-DCs+LPS). Data are expressed as means (+SD) of six different experiments and statistical analysis was determined by Student't test. The significant levels of both IL-12 and IL-10 between imDCs+LPS and *Msm*-DCs+LPS, compared to imDC(*) were p<0.05.

BCG-DCs induce Th2-like immune response in CBMCs and impair the immune response in naïve CD4$^+$CD45RA$^+$ T cells

Dendritic cells have the ability to stimulate naive T lymphocytes and drive them into distinct classes of effector cells. Because of the particular pattern of cytokines produced by BCG-DCs, we speculated that this population of DCs could differ in its capacity to support T cell differentiation. ImDCs, LPS-DCs and BCG-DCs were cultured in the

presence of human naïve cord-blood mononuclear cells (CBMCs). CBMCs cultured with LPS-DCs produced high levels of IFN-γ and significantly less IL-4 (**Figure 15, panel A**). In contrast, CBMCs cultured with BCG-DCs produced high levels of IL-4 and low amount of IFN-γ. Since the particular pattern of immunoregulatory cytokines of BCG-DCs, we blocked the IL-10 produced by BCG-DCs using a neutralizing monoclonal antibody anti-IL-10, to verify the role of IL-10 in Th1/Th2 induced profile. Neutralizing monoclonal anti IL-10 antibody was able to prevent only partially IL-4 production in CBMCs.

In order to investigate if the production of IL-4 was due to the naïve CD4 polarization, we cultured BCG-DCs with CD4[+]CD45RA[+] T cells for 8 days. CD4[+]CD45RA[+] T cells co-cultured with BCG-DCs are not able to produce neither IFN-

γ nor IL-4 compared to CD4[+]CD45RA[+] T cells stimulated with LPS-DCs which produced IFN-γ as expected (**Figure 15, panel B**). These data show that BCG-infected monocytes differentiate into DCs inducing Th2-like response and unable to induce the production of IFN-γ, that is necessary to elicit a protective immune response against mycobacteria.

Martino A. et al. Journal of Leukocyte Biology, 190:1167-1176, 2004

Figure 15 Polarization by DCs derived from untreated imDCs, LPS-DCs and BCG-infected (BCG-DCs) monocytes. ImDCs, LPS-DCs and BCG-DCs were co-cultured with cord blood mononuclear cells (CBMCs) (panel A) or purified CD4[+] CD45RA[+] cells (panel B), and after 8 days of culture, the supernatants were collected and tested for IFN-γ and IL-4 by ELISA. Data are expressed as means (+SD) of six different experiments and statistical analysis was determined by non parametric t test. The significant levels (*) between IFN-γ and IL-4 induced by BCG-DCs and LPS-DCs (panel A and B) were $p<0.05$ and IFN-γ and IL-4 induced by BCG-DCs + αIL-10 in comparison with BCG-DCs were $p<0.05$.

***Msm*-DCs direct naïve T lymphocytes towards a mixed Th1/Th2 immune response**

We also analyzed the polarization capacity of the DCs population derived from *Msm*-infected monocytes. DCs were cultured in the presence of human CD4$^+$CD45RA$^+$ T lymphocytes, purified from cord-blood donors, for 8 days. The production of different cytokines by T lymphocytes co-cultured with imDCs, mDCs and *Msm*-DCs, was assessed by Cytokines Beads Assay (**CBA**) kits. *Msm*-DCs skewed the differentiation of T cells towards a mixed Th1/Th2 profile, since high levels of both IL-4 and IFN-. (**Figure 16**). Other cytokines, such as IL-2 or TNF- were induced in mDCs compared to imDCs, whereas the levels of IL-2 and TNF-α were reduced in naïve T cells cultured with *Msm*-DCs. On the other hand, naïve T cells cultured with DCs maturated in the presence of LPS produced significantly less IL-4 and higher levels of IFN-γ and TNF−α. These data suggest that the early-matured *Msm*-DCs are able to prime naïve T cells towards a mixed Th1/Th2 response.

Figure 16. Cytokine accumulation in CD4⁺CD45RA⁺ T lymphocytes co-cultured with allogeneic DCs derived from *Msm*-infected monocytes or untreated monocytes. CD4⁺CD45RA⁺ T lymphocytes were purified from cord bloods of healthy donors, and cultured for 8 days with DCs derived from untreated monocytes (imDCs), from imDCs or DCs derived from *Msm*-infected monocytes and treated with LPS for 48 hours (mDCs or *Msm*-DCs). IL-2, IL-4, IFN-γ and TNF-α ⟨ were evaluated by CBA (Cytokines beads Assay) test in the supernatants of cultures. Data are expressed as means (+SD) of six different experiments and statistical analysis was determined by Student't test. The significant levels of IFNγ induced by mDCs or IL-4 and IFNγ induced by *Msm*-DCs compared to those of the imDCs (*) were p<0.05.

4. Discussion

Microorganisms [110, 111], cytokines [103, 105], tumor supernatants [115], gangliosides [113] and PPARy [116] activators can interfere in the early step of DCs differentiation from monocyte precursors generating "semi professional" APCs characterized by a less stimulatory mode. In this work we describe the generation of a phenotypically and functionally monocyte-derived DCs population that lacks IL-12 production, secretes increased levels of IL-10 and directs differentiation of T cell precursors towards the Th0/Th2-like phenotype. These cells were generated from human peripheral blood monocytes infected with tuberculosis vaccine BCG and cultured in the presence of GM-CSF and IL-4. These cytokines are released during inflammatory processes and sensitization procedures, including the vaccination with BCG, activating sequential production of Th1 and Th2 cytokines [117].

In the pathology of tuberculosis, the early interaction between DCs, present as a dense network in the airway mucosa, and *M. tuberculosis* is likely to be critical for mounting a protective anti-mycobacterial immune response [118]. However, *M. tuberculosis* infection remains much of the time in the lifetime of the host. The unique function of DCs in eliciting and directing the cellular immune response may be modulated by mycobacteria [119, 120]. Recently, it has been demonstrated that *M. tuberculosis* is able to subvert DCs differentiation of infected monocytes to escape immune response [111].

The benefits of the only available tuberculosis vaccine, BCG in the protection against *M. tuberculosis* have been debated since early in its use, including safety aspects, loss of sensitivity to tuberculin as a diagnostic reagent, and in particular the failure of BCG in a number of trials in the third world. There have been many

hypotheses to explain the inadequate protective effect of BCG against tuberculosis as the lack of an effective stimulation of T cell populations. However, in order to develop a novel vaccine strategy superior to BCG, fundamental immunological mechanisms responsible for protection, as well as reasons explaining the failure of BCG, still need to be fully resolved [121, 122].

We investigated whether the infection of monocytes with BCG could interfere with their differentiation into DCs and analyzed the capacity of BCG-DCs to direct T cell immune response. We found that BCG-infected monocytes differentiate into cells with an acquired mature phenotype, since they loss CD14, they express CD83 and up-regulate CD80, CD86, MHC class I and class II molecules in the absence of maturation stimuli. In addition, DCs generated from BCG-infected monocytes, express the CCR7 on their surface. The expression of this chemokine receptor in BCG-DCs is particularly relevant, since it allows homing to secondary lymphoid organs, where DCs can present antigens to specific T lymphocytes. It is known that during the differentiation of precursors into DCs, the cells acquire CD1a molecules on their surface, allowing them to present lipid and glycolipid antigens to T lymphocytes. However, BCG-DCs do not express CD1a molecules on their surface. In contrast, we found by confocal analyses that CD1a molecules are sequestrated in intracellular compartments. This finding is in accordance to previous investigations revealing that CD1 expression can be down-regulated by mycobacteria in infected DCs [62]. On the other hand, we wondered if the interference in DCs differentiation can be due to the simply stimulation of monocytes with a bacterial product such as LPS. We found that LPS-treated monocytes differentiate into imDCs showing a phenotype similar to the untreated cells except for the MHC class II up-regulation, suggesting that the treatment of monocytes with inflammatory stimuli do not completely account for the generation of DCs, presenting

an early mature phenotype. Although BCG-DCs show a mature phenotype at the fifth day of culture, they are not more efficient in stimulating T cells comparing to imDCs and LPS-DCs. However, upon further maturation stimuli their antigen presenting capacity is increased, showing that they are able to acquire the capacity of fully mDCs.

It has been suggested that the exposure to environmental mycobacteria interfere with the immune responses to tuberculosis and with the protective efficacy of BCG vaccination against pulmonary tuberculosis [80]. Environmental mycobacterial exposure might induce an impaired immune response towards common antigens shared by pathogenic and non pathogenic mycobacteria, which could interfere with the immune response to BCG vaccination. In this regard, a highly immunodominant antigen from *Msm* and other mycobacterial species has been identified [123]. Moreover, very little is known about the signaling events initiated in the monocytes following attachment of mycobacteria, neither pathogenic nor non-pathogenic species. We investigated whether the priming of monocytes with environmental, non pathogenic mycobacterium such as *Msm*, could have any effect on DCs differentiation and on the polarization of T cell immune response. We found that DCs differentiated from *Msm*-infected monocytes were CD1a- compared to control culture and other markers of DCs maturation were up-regulated. These findings demonstrate that the capacity to interfere with DCs phenotype during the differentiation of infected monocytes is common to different mycobacteria.

In particular, it is well known that group I CD1 molecules present glycolipids of the cell wall of mycobacterial species to a distinct group of T cells that secrete IFN-γ and are capable to kill infected target cells. The failure of CD1 expression by BCG-DCs could reduce the presentation of non peptide microbial antigens to CD1-restricted T cells, thus adversely affecting the anti-mycobacterial response that an effective vaccination against tuberculosis would require.

Regarding the functionality of DCs derived from BCG-infected monocytes, BCG-DCs acquire an activated phenotype at the fifth day since they produce pro-inflammatory cytokines such as TNF-α, IL-1β and IL-6, showing that they are able to elicit an inflammatory immune response. It has been reported, that the production of pro-inflammatory cytokines by APCs promotes the recruitment and activation of additional leukocytes playing a central role to limit the growth of intracellular pathogens [92].

Moreover, dendritic cells are known for their capacity to produce immunoregulatory cytokines such as IL-12 or IL-10 upon maturation stimuli. Therefore, the balance of the production of these cytokines plays a pivotal role by orchestrating both innate and acquired immune response and determining the polarization of T cell precursors. Interestingly, we found that BCG-DCs either before or after maturation stimuli produce high levels of IL-10 and are not able to produce IL-12 levels comparable with imDCs. In contrast, DCs derived from *Msm*-infected monocytes, produced high levels of IL-10 but they retained the capacity to produce IL-12. This difference can be correlated to the incapacity of *Msm* to persist in professional phagocytes. The profile of cytokines produced by these DCs defines an important difference in the interference on DCs functions between BCG and *Msm*.

The apparent disagreement of our findings with earlier studies which showed that BCG is a trigger of IL-12 production and maturation of DCs can be reconciled on the grounds that cytokine production are differentially modulated, depending on the timing and the maturation stage of target cells. Indeed, in our model we infected human monocytes and not differentiated DCs as it was in other experimental studies [124, 125]. The secretion of IL-10 and the inhibition of IL-12 synthesis, can account for the inability of

BCG-DCs to induce the expansion of effector Th1 lymphocytes. Indeed, BCG-DCs induce a Th2-like immune response when cultured with cord blood mononuclear cells as shown by high levels of IL-4 and low amounts of IFN-γ production. However, the production of IL-10 by BCG-DCs can not completely takes account for the IL-4 production, since neutralizing anti-IL-10 antibodies did not reverse completely the cytokine profile. Furthermore, purified CD4$^+$CD45RA$^+$ T cells co-cultured with BCG-DCs were not able to produce neither IL-4 nor IFN-γ. These results could be explained by the presence of multiple cell types in CBMCs able to produce IL-4 such as CD8$^+$ T cells. The loss of IFN-γ-producing T cells could be associated with a non protective immune response and an ineffective role in the killing of intracellular bacteria by macrophages. Several studies indicate that the IFN-γ is the key cytokine in the control of *M. tuberculosis* infection, triggering the anti-mycobacterial mechanism of macrophages in synergism with TNF-α [23, 126]. The difference of immunoregulatory cytokines produced by DCs derived from BCG and *Msm* infected monocytes, correlates also with the polarization capacity of these DCs populations. Indeed, *Msm*-DCs induce a mixed Th1/Th2 immune response when co-cultured with naïve CD4$^+$ T cells purified from cord-blood mononuclear cells, as shown by high levels of IL-4 together with high levels of IFN-γ production. These data show that the infection of monocytes with *Msm* is able to modulate the immune response modifying the production of immune regulatory cytokines. The infection of circulating monocytes by the exposure to environmental mycobacteria, could lead to the generation of DCs able to support the differentiation of Th1 and Th2 cells specific for antigens shared by pathogenic and non-pathogenic mycobacteria. The induction of mycobacteria-specific IFN-γ producing T cells by DCs generated from infected precursors could be associated with the inhibition

of BCG growth and thereby with a prevention of an efficient BCG-mediated immune response and protection against tuberculosis. On the other hand, mycobacteria-specific IL-4 producing T cells could be associated with a switch of the immune response in the control of inflammatory process during a secondary exposure to pathogenic mycobacterial infection.

Our hypothesis suggests that BCG, during vaccination, induces two different types of DCs populations. In the first step, BCG induce the maturation of resident DCs that produce IL-12 and able to expand Th1 T cells. The following multiplication of BCG implicates the exposure of BCG to recruited precursors. We hypothesize that in this step of exposure; BCG can infect recruited DCs precursors and induce them to differentiate into DCs with a mature phenotype producing pro-inflammatory cytokines that are responsible to amplify the response by promoting the recruitment of additional leukocytes. Dendritic cells derived from BCG-infected monocytes migrate to secondary lymphoid organs and produce high levels of IL-10 inducing a Th2-like immune response. Our hypothesis is represented in the figure below.

The figure shows the representation of what can occurs during the BCG vaccination. In the first step, BCG induces the maturation of resident DCs and infects precursors recruited by chemokines produced in the microenvironment. These cells differentiate into DCs population (BCG-DCs) able to expand Th2-like cells (black cells).

These results could account for the inflammatory response induced by BCG vaccination and could explain one of mechanisms underling the failure of BCG vaccine to prevent pulmonary tuberculosis and the influence of non pathogenic environmental mycobacteria in the immune response.

5. Acknowledgements

I would like to thank firstly the "Piccoletta" for her encouragement and because in the last year she became the most important person of my life. Thanks dear friends and colleagues of National Institute for Infectious Diseases "L. Spallanzani", this trip was less difficult because of you; thanks dear Silvia for your scientific support and friendship; thanks Giovanni, dear friend, because you divided with me all the problems of this PhD course. Thanks Prof. Vittorio Colizzi, you always had the right words for me. A particular thank is due to Fabrizio and Dr. Giuseppe Ippolito who approved and supported my stage in the Institute.

6. References

1. World Health Organization report. Global tuberculosis control, WHO/CDS/TB/2001.287

2. Hawken M., Nunn P., Gathua S. et al. Increased recurrence of tuberculosis in HIV-infected patients in Kenya. *Lancet* 342: 332-337, 1993

3. Spence DP., Hotchkiss J., Williams CS., Davies PD. Tuberculosis and poverty. *Brit Med. J.* 307: 759-761, 1993

4. Ityavyar DA. Health service inequalities in Nigeria. *Soc. Sci. Med.* 27: 1223-1235, 1988

5. Butler D. Consortium aims to kick-start TB research. *Nature* 403: 692-696, 2000

6. Grange JM. The mystery of the mycobacterial persister. *Tubercle Lung Dis.* 73: 249-251, 1992

7. Siegele DA., Kolter R. Life after log. *J. Bacteriol* 174: 345-348, 1992

8. Opie EL., Aronson JD. Tubercle bacilli in latent tuberculosis lesions and in lung tissue without tuberculosis lesions. *Arch Pathol Lab Med* 4: 1-21, 1927

9. Dhillon J. Allen BW., Hu YM., Coates AR., Mitchison DA. Metronidazole has no antibacterial effect in Cornell model murine tuberculosis. *Int. J. Tuberc Lung. Dis.* 2: 736-742, 1998

10. Wayne LG. Dormancy of Mycobacterium tuberculosis and latency of disease. *Eur J. Clin. Microbiol Infect Dis.* 13: 908-914, 1994

11. Koch R. Fortsetzung Yber ein Helmittel gegen Tubcerculose. Deutsh Med Wochenschr 17: 101-102, 1891

12. Wilson GS., Schwabacher H., Maier I. The effect of the desensitization of tuberculosis guinea pigs. *J. Path Bact* 50: 89-109, 1940

13. Balasubramanian R., Sivasubramanian S., Vijayan VK., et al. Five years results of a 3 month and two 5 month regimen for the treatment of sputum-positive pulmonary tuberculosis in South India. *Tubercle* 71: 253-258, 1990

14. Kaufmann SHE. How can immunology contribute to the control of tuberculosis? *Nature Rev. Immunol.* 1: 20-30, 2001

15. Sturgill-Koszycki S., Schlesinger P., Charkroborty P., Haddix P., Collins H., Fok A., Allen R., Gluck S., Heuser J., Russel D. Lack of acidification in Mycobacterium tuberculosis phagosomes produced by exclusion of the vescicular proton-ATPase. Science 263:678- 682, 1994

16. Lurie MB. Resistance to tuberculosis: experimental studies in native and acquired defense mechanisms. *Harvard University Press, Cambridge, Mass* 1964.

17. Dannenberg AM. jr., Rook GA. Pathogenesis of tuberculosis: an interplay between tissue-damaging and macrophage-activating immune responses: dual mechanism that control bacillary multiplication. *ASM Press, Washington D.C.,* 1994

18. Clerici M., Shearer GM. The Th1-Th2 hypothesis of HIV infection: new insights. *Immunol today* 15: 575-581, 1994

19. Salgame PR., Abrams JS., Clayberger C. Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. *Science* 254: 279-282, 1991

20. Ladel CH., Daugelat S., Kaufmann SHE. Immune response to Mycobacterium bovis bacille Calmette Guerin infection in major histocompatibility complex class I and II-deficient knock-out mice: contribution of CD4 and CD8 T cells to acquired resistance. *Eur J. Immunol* 25: 377-384, 1995

21. Dalton DK., Pitts-Meek S., Keshav S., Figari IS., Bradley A., Stewart TA: Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. *Science* 259:1739-1742, 1993

22. Cooper AM., Dalton DK. Stewart TA., Griffin JP., Russel DG., Orme IM., Disseminated tuberculosis in interferon-gamma gene disrupted mice. *J. Exp. Med.* 178: 2243-2247, 1993

23. Flyin JL., Chain J., triebold KJ., Dalton DK., Stewart TA., Bloom BR. An essential role for interferon-gamma in resistance to Mycobacterium tuberculosis infection. *J. Exp. Med.* 178: 2249-2254, 1993

24. Sugawara I., Yamada H., Kaneko H., Mizuno S., Takeda K., Akira S. Role of interleukin-18 (IL-18) in mycobacterial infection in IL-18-gene disrupted mice. *Infect Immun* 67: 2585-2589, 1999

25. Thompson SL., Skamene E., Radziock D. Acquired resistance but not innate resistance to *Mycobacterium bovis* bacillus Calmette Guerin is compromised by interleukin 12 ablation. *Infect Immun* 66: 5268-5274, 1998

26. Wakeman J., Wang J., Magram J et al. Lack of both types 1 and types 2 cytokines, tissue inflammatory responses, and immune protection during pulmonary infection by *Mycobacterium bovis* Bacillus Calmette Guerin in IL-12 deficient mice. *J. Immunol.* 160: 6101-6111, 1998

27. Hernandez-Pando R., Pavon L., Arriga K., orozco H. Madrid-Marina V., Rook GAW. Pathogenesis of tuberculosis in mice exposed to low and high doses of an environmental mycobacterial saprophyte. *Infect Immun* 65: 3317-3327, 1997

28. Hernandez-Pando R., Orozco H., Sampieri A. et al. Correlation between kinetics of Th1/Th2 cells and pathology in a murine model of experimental pulmonary tuberculosis. *Immunology* 89: 26-33, 1996

29. North RJ. Mice incapable of making IL-4 or IL-10 display normal resistance to infection with *Mycobacterium tuberculosis. Clin Exp. Immunol* 113: 55-58, 1998

30. Torres M. Herrera T., Villareal H., Rich EA., Sada E. Cytokine profiles for peripheral blood lymphocytes from patients with active pulmonary tuberculosis and healthy household contacts in response to the 30 kilodalton antigen of *Mycobacterium tuberculosis*. *Infect Immun* 66: 403-409, 1999

31. Wilkinson RJ., Wilkinson KA., De SK et al. Human T and B-cell reactivity to the 16kDa alpha-crystallin protein of *Mycobacterium tuberculosis*. *Scand J. Immunol* 48: 176-180, 1998

32. Verbon A., Juffermans N., Van DS et al Serum concentrations of cytokines in patients with active tuberculosis (TB) and after treatment. *Clin Exp Immun* 115:110-113, 1999

33. Andersen P. Host responses and antigens involved in protective immunity to *Mycobacterium tuberculosis*. *Scand J. Immunol* 45: 115-131, 1997

34. Bothamley GH., Beck JS., Schrender GM., D'Amaro J., De Vries RR., Kardjito T., Ivanyi J. Association of tuberculosis and *M.tuberculosis*-specific antibody levels with HLA. *J. Infect Dis.* 159: 549-555, 1989

35. Goldfeld AE. Delgado JC., Thim S., Bozon MV., Ugliadoro AM., Turbay D., Cohen C., Yunis EJ. Association of an HLA-DQ allele with clinical tuberculosis. *JAMA* 279: 226-228, 1998

36. Rajalingam R., Mebra NK., Mebra RD., Neolia S., Jain RC., Pande JN. HLA class I profile in Asian Indian patients with pulmonary tuberculosis. *Indian J Exp. Med* 35: 1055-1059, 1997

37. Flyinn JL. Goldstein MM., Triebold KJ., Koller B., Bloom BR. Major histocompatibility complex class I-restricted T cells are required for resistance to *Mycobacterium tuberculosis* infection. *Proc Natl Acad Sci USA* 89: 12013-12017, 1992

38. Leveton C., Barnass S., Champion B et al. T cell mediated protection of mice against virulent Mycobacterium tuberculosis. *Infect Immun* 57: 390-395, 1989

39. Bonato VL., Lima VM., Tascon RE., Lowrie DB., Silva CL. Identification and characterization of protective T cells in hsp65 DNA-vaccinated and *Mycobacterium tuberculosis*-infected mice. *Infect Immun* 66: 169-175, 1998

40. Mazzaccaro RJ., Stenger S., Rock KL. et al. Cytotoxic T lymphocytes in resistance to tuberculosis. *Adv Exp. Med Biol* 452: 85-101, 1998

41. Teitelbaum R., Cammer M., Maitland ML., Freitag NE., Condeelis J., Bloom BR. Mycobacterial infection of macrophages results in membrane-permeable phagosomes. *Proc Natl Acad Sci USA* 96: 15190-15195, 1999

42. Canaday DH., Ziebold C., Noss EH., Chervenak KA., Harding CV., Boom WH. Activation of human CD8+ alpha beta TCR + cells by *Mycobacterium tuberculosis* via an alternate class I MHC antigen processing pathway. *J. Immunol* 162: 372-379, 1999

43. Wren BW., Stabler RA., Das SS. et al. Characterization of a haemolysin from *Mycobacterium tuberculosis* with homology to a virulence factor of serpulina hyodysenteriae. *Microbiology* 1205-1211, 1998

44. Hess J., Miko D., Catic A., Lehmensiek V., Russel DG., Kaufmann SH. *Mycobacterium bovis* bacille Calmette Guerin strains secreting listeriolysin of *Listeria Monocytogenes. Proc Natl Acad Sci USA* 95: 5299-5304, 1998

45. Stenger S., Hanson DA., Teitelbaum R et al. An antimicrobial activity of cytolytic T cells mediated by granulolysin. *Science* 282: 121-125, 1998

46. Fazal N., Lammas DA., Rahelu M., Pithie AD., Gaston JS., Kumararatne DS. Lysis of human macrophages by cytolytic CD4+ T cells fails to affect survival of

intracellular *Mycobacterium bovis*-Bacille Calmette Guerin (BCG). *Clin Exp Immunol* 99: 82-89, 1995

47. Cooper AM., D'Souza C., Frank AA., Orme IM. The course of *Mycobacterium tuberculosis* infection in the lungs of mice lacking expression of either perforin- or granzyme-mediated cytolytic mechanisms. *Infect Immun* 65: 1317-1320, 1997

48. Laochumroonvarapong P. Wang J., Liu CC. et al. Perforin, a cytotoxic molecule which mediates cell necrosis, is not required for the early control of mycobacterial infection in mice. *Infect Immun* 65: 4850-4857, 1997

49. Tascon RE., Stavropoulos E., Lukacs KV., Colston MJ. Protection against *Mycobacterium tuberculosis* infection by CD8 T cells requires the production of gamma interferon. *Infect Immun* 66: 830-834, 1998

50. Serbina NV., Flyinn JL. Early emergence of CD8 (+) T cells primed for production of type 1 cytokines in the lungs of *Mycobacterium tuberculosis*-infected mice. *Infect Immun* 67: 3980-3988, 1999

51. Lalvani A., Brookes R., Wilkinson RJ., et al. Human cytolytic and interferon gamma secreting CD8+ T lymphocytes specific for *Mycobacterium tuberculosis. Proc Natl Acad Sci USA* 95: 270-275, 1998

52. Lewinsohn DM., Alderson MR., Briden Aç., Riddell SR., Reed SG., Grabstein KH. Characterization of human CD8 T cells reactive with *Mycobacterium tuberculosis*-infected antigen presenting cells. *J. Exp. Med* 187: 1633-1640, 1998

53. Silver RF., Li Q., Boom WH., Ellner JJ. Lymphocyte-dependent inhibition of growth of virulent Mycobacterium tuberculosis H37Rv within human monocytes: requirement for CD4 + T cells in purified protein derivative-positive, but not in purified protein derivative-negative subjects. *J. Immunol* 160: 2408-2417, 1998

54. Gong J., Stenger S., Zack JA., et al. Isolation of mycobacterium reactive CD1 restricted cells from patients with human immunodeficiency virus infection. *J. Clin Invest* 101: 383-389, 1998

55. Porcelli SA., Modlin RL. The CD1 system: antigen presenting molecules for T cell recognition of lipids and glycolipids. *Annu Rev immunol* 17: 297-329, 1999

56. Rosat JP., Grant EP., Beckman EM., et al CD1-restricted microbial lipid antigen-specific recognition found in the CD8+ alpha beta T cell pool. *J. Immunol* 162: 366-371, 1999

57. Behar SM., Dasher CC., Grusby MJ., Wang CR., Brenner MB. Susceptibility of mice deficient in CD1d or TAP1 to infection with *Mycobacterium tuberculosis. J Exp Med.* 189: 1973-1980, 1999

58. Szalay G., Zugel U., Ladel CH., Kaufmann SH. Participation of group 2 CD1 molecules in the control of murine tuberculosis. *Microbes Infect* 1: 1153-1157, 1999

59. Stenger S., Mazzaccaro RJ., Wyemura K. et al., Differential effects of cytolytic T cell subsets on intracellular infection. *Science* 276: 1684-1687, 1997

60. Beckman EM., Porcelli SA., Morita CT., Behar SM., Furlog ST., Brenner MB. Recognition of a lipid antigen by CD1 restricted alpha beta + T cells. *Nature* 372: 691-694, 1994

61. Sieling PA., Chatterjee D., Porcelli SA., et al CD1-restricted T cell recognition of microbial lipoglycan antigens. *Science* 269: 227-230, 1995

62. Stenger, S., Niazi, K.R., Modlin, R.L. Down regulation of CD1 on antigen-presenting cells by infection of *Mycobacterium tuberculosis*. *J. Immunol.* 161: 3582-3588, 1998

63. Seha GT., Scott GM., Rook GA., Type 2 cytokine gene activation and its relationship to extent of disease in patients with tuberculosis. *J. Infect. Dis.* 181: 385-389, 2000

64. van Crevel R., Kayardi E., Preyers F., et al. Increased production of IL-4 by CD4+ and CD8 + T cells from patients with tuberculosis is related to the presence of pulmonary cavities. *J. Infect. Dis.* 181:1194-1197, 2000

65. Yong AJ., Grange JM., Tee RD., et al. Total and anti-mycobacterial IgE levels in serum from patients with tuberculosis and leprosy. *Tubercle* 70:273-279, 1989

66. Wilsher ML., Hagan C., Prestidge R., Wells AU., Murison G. Human *in vitro* immune responses to *Mycobacterium tuberculosis. Tuber. Lung Dis.* 79:371-377, 1999

67. Bergeron A., Bonay M., Kambouchner M. et al Cytokine pattern in tuberculosis and sarcoid granulomas. *J. Immunol* 159:3034-3043, 1997

68. Arinobu Y., Atamas SP., Otsuka T. et al. Antagonistic effects of an alternative splice variant of human IL-4, IL-4 delta 2, on IL-4 activities in human monocytes and B cells. *Cell. Immunol* 191:161-167, 1999

69. Rook GA., Carswell JW., Stanford JL**.** Preliminary evidence for the trapping of antigen-specific lymphocytes in the lymphoid tissue of anergic tuberculosis patients. *Clin Exp Immunol* 26:129-132, 1926

70. Dieli F., Friscia G., Di SC, et al Sequestration of T lymphocytes to body fluids in tuberculosis: reversal of anergy following chemotherapy. *J. Infect Dis* 180:225-228, 1999

71. Hernandez-Pando R., Rook GAW. The role of TNF-α in T cell mediated inflammation depends on Th1/Th2 cytokine balance. *Immunology* 82:591-595, 1994

72. Bretscher PA., Wei G., Menon JN., Bielefeldt-Ohmann H. Establishment of stable, cell mediated immunity that makes susceptible mice resistant to Leishmania major. *Science* 257:539-542, 1992

73. Stanford JL., Shield MJ., Rook GAW. How environmental mycobacteria may predeterminate the protective efficacy of BCG. *Tubercle* 62:55-62, 1981

74. Ellner JJ. Regulation of the human immune response during tuberculosis. *J. Lab Clin Med* 130:469-475, 1997

75. American Academy of Pediatrics. Tuberculosis-BCG vaccine. In Pickering UK, ed. 2000 Red Book; Report of the Committee on Infectious Diseases. 25th edn. Ek Grove Village, II: *American Academy of Pediatrics*,612: 2000

76. McMurray DN. Disease Model-Pulmonary Tuberculosis. *Trends Mol Med* 7:135-137, 2001

77. Haebner RE. Bacillus Calmette-Guerin (BCG) vaccine in tuberculosis (WN. Rom, S. Garay, eds), *New York, Little, Brown and Company*, 893-904.

78. Behr, M.A., Small, P.M. Has BCG attenuated to impotence? *Nature.* 389:1330-1347, 1997

79. Cooper AM., Callahan JE., Keen M., Belisle JT., Orme IM. Expression of memory immunity in the lung following re-exposure to Mycobacterium tuberculosis. *Tuber Lung Dis.*78:67-73, 1997

80. Brandt L., Cunha JF., Olsen AW., Chilima B., Hirsch P., Appelberg R., Andersen P. Failure of *Mycobacterium bovis* BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infection and Immunity 70:672-678, 2002

81. Fine PE., The BCG story: lessonsfrom the past and implications for the future. *Rev. Infect. Dis.* 11(suppl. 2):353-359, 1989

82. Colditz GA., Berkey CS., Mosteller F., Brewer TF., Wilson ME., Burdick E., Fineberg HV. The efficacy of bacillus Calmette Guerin vaccination of newborns and infants in the prevention of tuberculosis: metanalisyses of the published literature. *Pediatrics* 96:29-35, 1995.

83. Kamalia TC., Paramasivan CN., Herbert D., Verkatesan P., Prabhakar R. Immune response & modulation of immune response induced in the guinea pigs by Mycobacterium avium complex (MAC) % M. fortuitum complex isolates from different sources in the South Indian BCG trial area. *Indian J. Med. Res.* 103:201-211, 1996

84. Palmer CE., Long MW. Effects of infection with atypical mycobacteria on BCG vaccination and tuberculosis. *Am Rev. Respir Dis*. 94:553-568, 1966.

85. Banchereau J., Steinman R. Dendritic cells and the control of the immunity. *Nature* 392: 245-252, 1998

86. Cella M., Sallusto F., Lanzavecchia, A. Origin, maturation and antigen presenting function of dendritic cells. *Curr. Opin Immunol* 9:10-16, 1997

87. Banchereau J., Briere F., Caux C. Immunobiology of dendritic cells. Annu Rev. Immunol 18: 767-811, 2000

88. Lanzavecchia A., Sallusto F. Regulation of T cell immunity by dendritic cells. Cell 106: 263-266, 2001

89. Sousa CR., Hieny S., Scharton-Kersten T. et al. *In vivo* antimicrobial stimulation induces the rapid CD40-ligand-independent production of IL-12 by dendritic cells and their redistribution to T cell areas. *J. Exp. Med.* 186:1819-1829, 1997

90. Inaba K., Inaba M., Romani N. et al. Generation of large number of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. *J. Exp. Med.* 176:1693-1702, 1992

91. Romani N., Gruner S., Brang D. et al. Proliferating dendritic cell progenitors in human blood. *J. Exp. Med.* 180:83-93, 1994

92. Henderson RA., Watkins SC., Flyinn JL. Activation of human dendritic cells following infection with *Mycobacterium tuberculosis. J. Immunol* 159: 635-643, 1997

93. Thurnher M., Ramoner R., Gastl G. et al. Bacillus Calmette Guerin mycobacteria stimulate human blood dendritic cells. *Int. J. Cancer* 70:128-134, 1997

94. Demangel C., Bean AGD., Martin E. et al. Protection against aereosol *Mycobacterium tuberculosis* infection using *Mycobacterium bovis* Bacillus Calmette Guerin-infected dendritic cells. *Eur. J. Immunol.* 23:1972-1979, 1999

95. Sieling PA., Jullien D., Dahlem M. et al. CD1 expression by dendritic cells in human leprosy lesions: Correlation with effective host immunity. *J. Immunol* 162:1851-1858, 1999

96. Britton WJ., Roche PW., Winter N. Mechanisms of persistence of mycobacteria. *Trends Microbiol* 2:284-288, 1994

97. Cooper AM., Magram J., Ferrante J. et al. Interleukin 12 is crucial to the development of protective immunity in mice intravenously infected with *Mycobacterium tuberculosis. J. Exp. Med.* 186:39-45, 1997

98. Hernandez-Pando R., Orozco H., Arriaga K. et al. Analysis of the local kinetics and localization of interleukin 1a, tumour necrosis factor α and transforming growth factor β, during the course of experimental pulmonary tuberculosis. *Immunology* 90:607-617, 1992

99. Demangel C., Britton WJ. Interaction of dendritic cells with mycobacteria: where the action strats. *Immunology and Cell Biology* 78:318-324, 2000

100. Murray PJ., Young RA. Increased antimycobacterial immunity in interleukin 10 deficient mice. *Infect Immun* 67:3087-3095, 1999.

101. Orme JM., Cooper AM. Cytokine chemokine cascade in immunity to tuberculosis. *Immunol Today* 20:307-312, 1999.

102. Chapuis, F., Rosenzwajg, M., Yagello, M., Ekman, M., Biberfeld, P., Gluckman, J.C. Differentiation of human dendritic cells from monocytes *in vitro*. *Eur. J. Immunol* 27: 431-441, 1997

103. Delneste, Y., Charbonnier, P., Herbault, N., Magistrelli, G., Caron, G., Bonnefoy, J.Y., Jeannine, P. Interferon-gamma switches monocyte differentiation from dendritic cells to macrophages. *Blood* 101(1), 143-150, 2003

104. Randolph, G.J., Bealieu, S., Lebecque, S., Steinman, R.M., Muller, W.A. Differentiation of monocytes into Dendritic Cells in a model of trans-endothelial trafficking. *Science* 284: 480-483, 1998

105. Chomorat, P., Banchereau, J., Davoust, J., Palucka, A.K. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. *Nat. Immunol.* 1, 510-514, 2000

106. Zhou, L.J., Tedder, T.F. CD14[+] blood monocytes can differentiate into functionally mature CD83[+] dendritic cells. *PNAS* 93, 2588-2592, 1996

107. Lyakh, L.A., Koski, G.K., Telford, W., Gress, R.E., Cohen, P.A., Rice, N.R. Bacterial lipopolysaccharide, TNF-α and calcium ionophore under serum-free conditions promote rapid dendritic cell-like differentiation in CD14[+] monocytes through distinct pathways that activate NK-kB. *J. Immunol* 165(7), 3647-3655, 2000

108. Rosenzwaig, M., Jarquin, F., Tailleux, L., Gluckman, J.C. CD40 ligation and phagosytosis differently affect the differentiation of monocyte into Dendritic cell. *J. Leukoc Biol* 72(6), 1180-1189, 2002

109. Dolganiuc A, Kodys K., Kopasz A., Marshall C., Do T., Romics L. Jr, Mandrekar P., Zapp M., Szabo G. Hepatitis C virus core and nonstructural protein 3 proteins induce pro- and anti-inflammatory cytokines and inhibit dendritic cell differentiation. *J Immunol* 170(11):5615-5624, 2003

110. Guerreiro-Cacais AO., Li L., Donati D., Bejarano MT., Morgan A., Masucci MG., Hutt-Fletcher L., Levitsky V. Capacity of Epstein-Barr virus to infect monocytes and inhibit their development into dendritic cells is affected by the cell type supporting virus replication. *J Gen Virol.* 85::2767-2778, 2004

111. Mariotti S., Teloni R., Iona E., Fattorini L., Giannoni F., Romagnoli G., Orefici G., Nisini R. *Mycobacterium tuberculosis* subverts the differentiation of human monocytes into dendritic cells. *Eur. J. Immunol* 32: 3050-3058, 2002

112. Chang C.C., Wright A., Punnonen J. Monocyte-derived CD1a^{+} and CD1a^{-} Dendritic cell subsets differ in their cytokine production profiles, susceptibility to transfection, and capacities to direct Th cell differentiation. *J. Immunol* 165: 3584-3591, 2000

113. Péguet-Navarro J., Sportouch M., Popa I., Berthier O., Schmitt D., Portoukalian J. Gangliosides from human melanoma tumors impair dendritic cell differentiation from monocytes and induce their apoptosis. *J. Immunol.* 170, 3488-3494, 2003

114. Falcone V., Bassey EB., Toniolo A., Conaldi PG., Collins FM. Differential release of tumor necrosis factor-α from murine peritoneal macrophages stimulated with virulent and avirulent species of mycobacteria. *FEMS Immunol Med Microbiol* 8:225-232, 1994

115. Sombrock CC., Stam AG., Masterson AJ., Lougheed SM., Schakel MJ., Meijer CJ et al. Prostanoids play a major role in the primary-induced inhibition of dendritic cells differentiation. *J. Immunol*. 168:4333-4343, 2002.

116. Nencioni A., Grunebach F., Zobywlaski A., Denzlinger C., Bruger W., Brossart P. Dendritic cell immunogenicity is regulated by peroxisome proliferatopr-activated receptor gamma. *J. Immunol* 169:1228-1235, 2002.

117. Sander B., Skannsen-Saphir, U., Damm, O., Hakansson, L., Anderson, J., Andersson, U. Sequential production of Th1 and Th2 cytokines in response to live bacillus Calmette-Guerin. *Immunology* 86: 512-518, 1995

118. Giacobini E., Iona E., Ferroni L., Miettinen M., Fattorini L., Orefici G., Julkunen I., Coccia E.M. Infection of human macrophages and dendritic cells with *Mycobacterium tuberculosis* induces a differential cytokine gene expression that modulates T cell response. *J. Immunol* 166: 7033-7041, 2001

119. Nigou J., Zelle-Rieser C., Gilleron M., Thurnher M., Puzo G. Mannosylated lipoarabinomannans inhibit IL-12 production by human dendritic cells: evidence for a negative signal delivered through the mannose receptor. *J. Immunol.* 166, 7477-7485, 2001

120. Dahl KE., Shiratsuchi H., Hamilton BD., Ellner, JJ., Toossi, Z. Selective induction of transforming growth factor-β in human monocytes by lipoarabinomannan of *Mycobacterium tuberculosis*. *Infect. Immun.* 64: 399-405, 1993

121. Agger, EM., Andersen P. A novel TB vaccine towards a strategy based on our understanding of BCG failure. *Vaccine* 21(1-2), 7-14, 2002

122. Orme IM. The search for new vaccines against tuberculosis. *J. Leukoc Biol* 70: 1-10, 2001

123. Prasad R., Yadav G. Identification of a 75 kDa highly immunodominant antigen from *Mycobacterium smegmatis* and cross-reactivity with other species. *Indian J. Exp. Biol.* 39:255-262, 2001

124. Liu E., Law HK., Lau YL. BCG promotes cord blood monocyte-derived dendritic cell maturation with nuclear Rel-B up-regulation and cytosolic I kappa B alpha and beta degradation. *Pediatr Res.* 54(1): 105-112, 2003

125. Martino A., Sacchi A., Sanarico N., Spadaro F., Ramoni C., Ciaramella A., Pucillo L.P., Colizzi V., Vendetti S. Dendritic cells derived from BCG-infected precursors induce Th-2 like immune response. *Journal of Leukoc Biology 76: 827-834, 2004*

126. Pathan AA., Wilkinson KA., Klenerman P., McShane H., Davidson RN., Pasvol G., Hill AV., Lalvani A. Direct ex vivo analysis of antigen specific IFN-gamma-secreting CD4 T cells in *Mycobacterium tuberculosis*-infected individuals; associations with clinical disease state and effect of treatment. *J. Immunol* 167, 5217-5225, 2001

List of publications during the PhD course in Immunology

by Dr. Angelo Martino

1. Ciaramella A., **Martino A.**, Cicconi R., Colizzi V. and Fraziano M. Mycobacterial 19-kDa lipoprotein mediates *Mycobacterium tuberculosis*-induced apoptosis in monocytes/macrophages at early stages of infection. *Cell Death and Differentiation* 7:1270-1272, 2000.

2. Mariani F., Goletti D., Ciaramella A., **Martino A.**, Colizzi V. and Fraziano M. Macrophage response to *Mycobacterium tuberculosis* during HIV infection. Relationships between macrophage activation and apoptosis. *Current Molecular Medicine* 1: 209-216, 2001.

3. **Martino A.**, Vismara D., Cicconi R., Delpino A., Ivanyi J., Colizzi V., Cassol M., Fraziano M., Piselli P. Effective anti-tumor immunity induced in mice by a two-step vaccination protocol. *In vivo* 15(5): 425-428, 2001.

4. Ciaramella A., Cavone A., Santucci M.B., Amicosante M., **Martino A.,** Auricchio G., Pucillo L.P., Colizzi V., Fraziano M. Pro-inflammatory cytokines in the course of *Mycobacterium tuberculosis*-induced apoptosis in monocytes/macrophages. *Journal Infectious Disease*, 186:1277-82, 2002

5. Baldini P.M., De Vito P., **Martino A.**, Fraziano M., Grimaldi C., Luly P., Zalfa F., Colizzi V. Differential sensitivity of monocytes and macrophages to ANP: the role of intracellular pH on reactive oxygen species production throughout the phospholipase involvement. *Journal Leukocyte Biology* 73(4):502-510, 2003.

6. **Martino A.**, Auricchio G., Garg S., Volpe E., Ciaramella A., De Vito P., Baldini P.M., Colizzi V., Fraziano M. Role of macrophage phospholipase D in natural and CPG-induced anti-mycobacterial activity. *Cellular Microbiology 5 (12), 913-920, 2003.*

7. Garg S.K., Volpe E., Palmieri G., Mattei M., Galati D., **Martino A.**, Piccioni M.S., Valente E., Bonanno E., De Vito P., Baldini M.P., Spagnoli L.G., Colizzi V., Fraziano M. Sphingosine 1-phosphate induces antimicrobial activity both *in vitro* and *in vivo*. *Journal Infectious Diseases 189: 2129-2138, 2004.*

8. **Martino A.**, Sacchi A., Sanarico N., Spadaro F., Ramoni C., Ciaramella A., Pucillo L.P., Colizzi V., Vendetti S. Dendritic cells derived from BCG-infected precursors induce Th-2 like immune response. *Journal of Leukocyte Biology, 76:827-834, 2004*

9. Ciaramella A., Cavone A., Santucci M.B., Garg S.K., Sanarico N., Bocchino M.L., Galati D., **Martino A.**, Auricchio G., D'Orazio M., Stewart G.R., Neyrolles O., Young D.B., Colizzi V. Fraziano M. Induction of apoptosis and release of IL-1β by cell wall associated 19-kDa lipoprotein during mycobacterial infection. *Journal of Infectious Diseases 190: 1167-1176, 2004*

10. Conti L., Casetti R., Cardone M**.,** Varano B., **Martino A.,** Belardelli F., Poccia F., Gessani S. Reciprocal activating interaction between dendritic cells and pamidronate-stimulated γδ T cells: role of CD86 and inflammatory cytokines. *Journal of Immunology* 174:252-260, 2005

11. Martino A., Casetti R., D'Alessandri A., Sacchi A., Poccia F. Complementary function of γδ T lymphocytes and Dendritic Cells in the response to isopentenylpyrophosphate and lipopolisaccharide antigens (*submitted to Journal of Clinical Immunology*)

12. **Martino A.,** Sacchi A., Volpe E., Agrati C., De Santis R., Colizzi V., Vendetti S. Non pathogenic *Mycobacterium smegmatis* induces the differentiation of human monocytes directly into fully mature dendritic cells (*submitted to Journal of Clinical Immunology*)

List of publications not indexed

North-South Transfer in Biotechnology of Tuberculosis and AIDS, UNESCO Report, 2004, edited by Colizzi V and Montagnier L.